






The role of Dot1l in normal hematopoiesis  




Stephanie Youngyoon Jo 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
(Molecular and Cellular Pathology) 












 Professor Jay L. Hess, Chair 
 Professor Ronald J. Koenig 
Professor Steven L. Kunkel 
 Associate Professor Raymond C. Trievel 
 Assistant Professor Ivan P. Maillard 















































Table of Contents 
 
Dedication                   ii 
List of Figures                  iv 
List of Tables               viii 
Abstract                          ix 
 
Chapter I: Introduction                1 
Chapter II: The role of Dot1l in postnatal hematopoiesis           9 
Chapter III: The role of Dot1l in MLL fusion protein-mediated leukemogenesis  31 
Chapter IV: Analysis of Dot1l lacking Tissue Sections          56 
Chapter V: Other Experiments and Preliminary Results: Expression Analysis of 
HSCs                 61 
Chapter VI: Other Experiments and Preliminary Results: Histone Cross-Talk    73 
Chapter VII: Other Experiments and Preliminary Results: Dot1l-AF9/ENL 
interaction                84 
Chapter VIII: Discussion              90 





List of Figures 
 
Figure 1.1. Wild type MLL protein complex.               4 
Figure 1.2. The most common MLL translocation protein complex           5 
Figure 2.1.  Generation of conditional Dot1l knockout mice.              11 
Figure 2.2. Prolonged loss of Dot1l in adult mice leads to death.          16 
Figure 2.3.  CBC analysis.                 17 
Figure 2.4. H & E stained section of bone marrow          18 
Figure 2.5. Baseline comparison of HSCs in mice lines.           20 
Figure 2.6.   Deletion of Dot1l led to loss of HSCs and progenitors.                    21 
Figure 2.7. Bar graph of population frequencies as defined in Figure 2.6.          22  
Figure 2.8. Schematic of competitive bone marrow transplantation experiment.   
                 23 
Figure 2.9. Bar graph of CD45.2+ cells in peripheral blood.                             24 
Figure 2.10.  Bar graph of CD45.2+ cells in recipient bone marrow and thymus 16 
weeks after transplantation.               25 
Figure 2.11.  Staining profile of recipient HSCs (lineage-, sca1+, ckit+, CD48-, 
CD150+) 16 weeks after transplantation.             26 
Figure 2.12. Schematic of bone marrow transplantation experiment for examining 
cell-autonomous HSC defect.                                   28 
Figure 2.13. HSC defects in Dot1l-deficient cells are cell-autonomous.              29 
 v 
Figure 2.14. Bar graph of bone marrow and thymus reconstitution by CD45.2+ 
cells 16 weeks after tamoxifen injection.                 30 
Figure 3.1.  Schematic of colony forming unit (CFU) assay.          36 
Figure 3.2.Genotyping of transduced cells after the second round.                    37 
Figure 3.3. Colony formation on methocult plates.            38 
Figure 3.4.  Bar graph of colony count at final round.            39 
Figure 3.5.  Bar graph of colony count with cells grown in liquid culture for >8 
weeks.                   39 
Figure 3.6.  Colony formation on methocult plates.          40 
Figure 3.7.  H3K79me2 western blot of Hoxa9/Meis1, E2A-HLF, and MLL-AF9 
transformed cells.                 41  
Figure 3.8.  Loss of Dot1l leads to growth impairment for MLL-AF9 transformed 
cells but not for Hoxa9/Meis1 or E2A-HLF transformed cells.         42 
Figure 3.9.  Time course of cell cycle analysis.           45 
Figure 3.10.  Quantification of cell cycle.            46 
Figure 3.11.  Annexin V staining of cell lines after Dot1l excision.        48  
Figure 3.12.  Annexin V staining for apoptosis assay.          49 
Figure 3.13.  The loss of Dot1l leads to selective loss of critical downstream 
target gene expression in MLL-AF9 transformed cells.           50  
Figure 3.14.  Schematic of Dot1l constructs.           51  
Figure 3.15.  Genotyping of transduced cells after the second round.         52 
Figure 3.16.  qPCR of exogenous Dot1l expression.            53 
Figure 3.17. Western blot of H3K79me2 after second round.          54 
 vi 
Figure 3.18.  Colony formation on methocult plates.            55 
Figure 3.19.  Bar graph of colony count at final round.           55 
Figure 4.1.  H3K79me2 immunohistochemical staining of representative Dot1l+/+ 
and Dot1lF/F tissue sections.               60 
Figure 5.1.  Time course of HSC staining profile after tamoxifen injection.         66 
Figure 5.2.  Heat map of altered gene expression with Dot1l excision in HSCs. 67 
Figure 5.3. GSEA pathway enrichment: EZH2 targets.          69 
Figure 5.4. GSEA pathway enrichment: Myeloid proliferation and self renewal. 70 
Figure 5.5. GSEA pathway enrichment: Granulocyte and monocyte differentiation.  
      71 
Figure 5.6. Propidium iodide cell cycle analysis of bone marrow cell population. 
      72 
Figure 6.1.  Western blot of whole cell lysate after Dot1l excision.        80 
Figure 6.2. H3K79me2 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.        81 
Figure 6.3. H3K4me3 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.          81 
Figure 6.4. Mll-C ChIP of Hoxa9 and Meis1 loci after Dot1l excision.                 82  
Figure 6.5. H3K27me3 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.        82 
Figure 6.6. H2Bub ChIP of Hoxa9 and Meis1 loci after Dot1l excision.         83 
Figure 6.7.  HA tagged Dot1l was overexpressed in 293 cells and 
immunoprecipitated (IP) with HA antibody.             83 
Figure 7.1. Alignment of C-terminus of human and mouse AF9 and ENL proteins. 
      84 
Figure 7.2.  Schematic of transduction of MLL-AF9 transformed cells.               86 
 vii 
Figure 7.3.  Genotyping of transduced bone marrow cells after first round.        86 
Figure 7.4.  qPCR of HA tag and N-terminus of Dot1l.           87 
Figure 7.5.  Western blot of H3K79Me2 after first round.           88 
Figure 7.6.  Quantification of colony formation by MLL-AF9 transformed cells with 
endogenous Dot1l excision and exogenous Dot1l constructs.         88 
Figure 7.7. Whole plate image of colony formation by MLL-AF9 transformed cells 




List of Tables 
Table 2.1. Genotyping primers.               11 
Table 2.2. Control and experimental mice genotype designation.          12 
Table 3.1 qPCR primers.              35 
Table 5.1 Top 20 changed genes with Dot1l excision in HSCs.           68 



















Disruptor of telomeric silencing 1-like (Dot1l) is a histone 3 lysine 79 
methyltransferase.   Studies of constitutive Dot1l knockout mice show that Dot1l 
is essential for embryonic development and prenatal hematopoiesis.  Dot1l also 
interacts with fusion partners of Mixed Lineage Leukemia (MLL) gene, which is 
commonly translocated in human leukemia.  However, the requirement of Dot1l 
in postnatal hematopoiesis and leukemogenesis of MLL translocation proteins 
have not been conclusively shown.  With conditional Dot1l knockout mouse 
model, we examined the consequences of Dot1l loss in postnatal hematopoiesis 
and MLL translocation leukemia.  Deletion of Dot1l led to pancytopenia and 
failure of hematopoietic homeostasis, and Dot1l-deficient cells minimally 
reconstituted recipient bone marrow in competitive transplantation experiments.  
In addition, MLL-AF9 cells required Dot1l for oncogenic transformation, while 
cells with other leukemic oncogenes such as Hoxa9/Meis1 and E2A-HLF did not.  
Furthermore, both histone methyltransferase activity of Dot1l and interaction with 
MLL fusion partner are required for transformation by MLL-AF9.  In addition, loss 
of Dot1l affected histone modification at select loci instead of leading to global 
changes.  These findings illustrate a crucial role of Dot1l in normal hematopoiesis, 







 Epigenetic modification is an important mechanism for the regulation of 
transcription and maintenance of cell identity with cell division.   Hence, many 
histone modifying enzymes have been identified as crucial for maintaining normal 
hematopoietic stem cells (HSCs) as well as leukemia initiating cells (LICs).  
Disruptor of telomeric silencing 1 (Dot1) is a novel class of histone 
methyltransferase that was first identified in yeast for its ability to dysregulate 
gene silencing near telomeres  (Feng et al., 2002; Min et al., 2003; Singer et al., 
1998).  Dot1, and its mammalian homologue, Dot1l (Dot1-like), is currently the 
only identified histone 3 lysine 79 (H3K79) methyltransferase (Ng et al., 2002a; 
van Leeuwen et al., 2002).  Since its discovery, many studies show an essential 
role for Dot1l and H3K79 methylation in leukemia, embryonic development, 
prenatal hematopoiesis, and histone cross-talk (Barry et al., 2010; 
Chandrasekharan et al., 2010; Slany, 2009).  However, the requirement of Dot1l 
in leukemogenesis and the role of Dot1l in the normal postnatal hematopoiesis 




Mixed Lineage Leukemia (MLL) gene  
The Hess lab became interested in Dot1l while studying leukemias arising 
from translocations of the Mixed Lineage Leukemia (MLL) gene.  Work done by 
the Hess laboratory and others has shown that the MLL C-terminal SET domain 
is a H3K4 methyltransferase (Milne et al., 2001; Nakamura et al., 2002).  Further 
studies have shown that MLL interacts with proteins RbBP5, WDR5, and Ash2L, 
for optimal H3K4 methyltransferase activity (Dou et al., 2006).  MLL also requires 
association with Menin, LEDGF, and MOF for its proper function (Dou et al., 
2005; Yokoyama and Cleary, 2008; Yokoyama et al., 2005; Yokoyama et al., 
2004).  Knockout mouse models have shown that MLL is particularly important 
for the correct Hox gene expression and maintenance.  MLL heterozygous (+/-) 
mice show slowed growth, hematopoietic abnormalities, and bidirectional shifts in 
Hox expression boundaries.  Complete MLL deficiency (-/-) is embryonic lethal 
and is associated with severe defects in HoxA and C cluster expression (Hanson 
et al., 1999; Yu et al., 1995).  However, the transgenic mice expressing Mll 
lacking the SET domain (Mll∆SET) exhibit altered transcription of Hox genes and 
loss of H3K4 methylation but remain viable (Terranova et al., 2006), indicating 
that regions of Mll other than the SET domain also have important biological 
activity.  This result is notable because the SET domain is lost with the majority 
of leukemia causing MLL translocations (Krivtsov and Armstrong, 2007; Meyer et 




MLL translocation leukemia   
 Translocations of MLL, located on chromosome band 11q23, are 
frequently found in acute leukemia and are associated with poor prognosis.  MLL 
rearrangements are particularly common in infant leukemia under the age of two, 
with 70-80% of cases exhibiting MLL translocation and pro-B cell lymphoid 
phenotype (Krivtsov and Armstrong, 2007; Rubnitz et al., 1994; Silverman, 2007; 
Taki et al., 1996).  MLL translocations are also found in roughly 10% of adult 
cases with acute myeloid leukemia (AML), involving over fifty different 
translocation partners in addition to those presenting with partial tandem 
duplications (Dou and Hess, 2008; Meyer et al., 2009).  While recent studies 
indicate important function of reverse translocation proteins such as AF4-MLL 
(Benedikt et al., 2011; Bursen et al., 2010), for the purpose of this thesis, MLL 
translocation refers to the fusion of the N-terminus of MLL and C-terminus of a 
translocation partner.   
Similar to wild type MLL, MLL fusion proteins upregulate the expression of 
the Hox loci along with the Hox cofactor Meis1, which are necessary and 
sufficient for transformation (Ayton and Cleary, 2003; Zeisig et al., 2004). 
Although rare MLL fusion partners are cytoplasmic proteins with self 
oligomerization domains (Martin et al., 2003; So et al., 2003), greater than 80% 
of the fusion partners are nuclear proteins, including AF4, AF9, ENL, AF10, and 
ELL, with  t(4;11) (MLL-AF4 fusion), t(11;19) (MLL-ENL fusion), and t(9;11) (MLL-
AF9 fusion) being most common (Dou and Hess, 2008; Huret et al., 2001; 
Krivtsov and Armstrong, 2007; Meyer et al., 2009).  Studies performed by the 
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Hess lab and others have shown that these common translocation partners form 
a coactivator complex along with the transcriptional elongation machinery pTEFb 
and chromatin modifier Dot1l (Bitoun et al., 2007; Mohan et al., 2010; Monroe et 
al., 2010; Mueller et al., 2007; Okada et al., 2006).  These studies on MLL and 
















Figure 1.1. Wild type MLL protein complex.  C-terminal MLL associates with 
other proteins for H3K4 methylation and H4K16 acetylation activity.  N-terminal 
MLL associates with LEDGF and Menin for proper gene regulation.  C-terminal 
MLL associates with RBBP5, ASH2L, and WDR5 for H3K4 methylation and also 
interacts with MOF that acetylates H4K16 residue.  Figure modified from Slany, 
















Figure 1.2. The most common MLL translocation protein complex.  The most 
common MLL translocation partners interact with each and other proteins that 
promote transcriptional elongation (pTEFb, phosphorylates RNA pol II C-terminal 
domain, CTD) and modify chromatin (DOT1L, methylates H3K79 residue). Figure 
modified from Slany, 2009.   
 
Dot1l and MLL translocation leukemias 
Dot1l is strongly associated with MLL translocation leukemias.  As 
mentioned above, multiple studies show that Dot1l interacts with many of the 
most common MLL translocation partners in a complex promoting transcriptional 
elongation (Bitoun et al., 2007; Mohan et al., 2010; Monroe et al., 2010; Mueller 
et al., 2007; Okada et al., 2006).  Additional evidence from MLL translocation 
containing cell lines and patient samples shows upregulation of H3K79 
methylation at MLL translocation target genes including HOXA9 and MEIS1, 
which are critical for leukemogenesis (Krivtsov et al., 2008; Monroe et al., 2010).   
Furthermore, the loss of H3K79 methylation through knockdown of Dot1l leads to 
reduced expression of these genes (Krivtsov et al., 2008; Monroe et al., 2010).   
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However, it is not clear if Dot1l is required for MLL translocation-mediated 
leukemogenesis, and if other leukemia oncogenes also require Dot1l.   
 
Gene regulation by Dot1l and H3K79 methylation  
In general, Dot1l and H3K79 methylation are associated with 
transcriptional activation (Karlić et al., 2010; Steger et al., 2008; Vakoc et al., 
2006).  Interestingly, the loss of Dot1l seems to regulate a relatively short list of 
genes instead of globally downregulating the entire transcriptome.  This effect 
has been particularly noted in the context of embryonic stem cells suggesting a 
specific biological role for Dot1l (Barry et al., 2009).  Further studies using 
constitutive Dot1l knockout mouse models provide additional evidences for a role 
of Dot1l in stem cell biology.  Analyses of Dot1l knock out embryonic stem cells 
and yolk sac cells show that the loss of Dot1l leads to cell cycle defects, 
chromosomal aberrations, and prenatal hematopoietic abnormalities (Feng et al., 
2010; Jones et al., 2008).  However, the two constitutive Dot1l knockout mouse 
lines are embryonic lethal by E10.5 and E13.5, precluding the examination of 
Dot1l loss in postnatal mice and in definitive hematopoiesis.   
 
Dot1l and histone cross-talk 
Dot1l is currently the only identified H3K79 methyltransferase.  Knockout 
models (Feng et al., 2010; Jones et al., 2008) and knock down studies (Barry et 
al., 2009; Jacinto et al., 2009) indicate that Dot1l is the major, if not the only, 
histone methyltransferase responsible for mono-, di-, and tri- H3K79 methylation.  
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Histone methyltransferase activity of Dot1l is quite unique, requiring the 
nucleosome for optimal activity unlike many other enzymes that can methylate 
histone peptides (Feng et al., 2002; Min et al., 2003).  Furthermore, studies show 
that H3K79 methylation requires H2B ubiquitination for enzymatic activity (Kim et 
al., 2009; Lee et al., 2007; Ng et al., 2002b; Wood et al., 2003).  It is also 
interesting that the same studies show a requirement of H2B ubiquitination for 
H3K4 methylation.  As mentioned above, MLL and DOT1L are closely associated 
through MLL translocation leukemias.  Hence, the histone cross-talk between 
H3K79 methylation, H2B ubiquitination, and H3K4 methylation is of interest.  In 
particular, there has been no study showing if H3K79 methylation is required for 
H2B ubiquitination or H3K4 methylation in a mammalian system.    
 
Rational of study 
Despite its importance in prenatal hematopoiesis and its association with 
MLL translocation leukemia, no conclusive data are available regarding the role 
of Dot1l in postnatal hematopoiesis and its requirement in leukemogenesis.  In 
addition, while histone cross-talk among H2B ubiquitination, H3K79 methylation, 
and H3K4 methylation is established in yeast, data in mammalian systems need 
further studies.  Since constitutive Dot1l inactivation leads to early embryonic 
lethality, we generated conditional Dot1l knockout mice and examined the 
consequences of Dot1l loss in postnatal hematopoiesis, leukemogenesis by MLL 
translocation, and histone modifications.  Dot1l was required for normal 
hematopoiesis under homeostatic conditions, and the loss of Dot1l led to the cell-
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autonomous failure of functional stem cells.  In addition, MLL translocation 
leukemia cells were selectively sensitive to the loss of Dot1l compared to cells 
transformed by other oncogenes such as Hoxa9/Meis1 and E2A-HLF.  
Furthermore, the loss of H3K79 methylation had minimal effects on global H2B 
ubiquitination and H3K4 methylation while having dramatic effects on Mll target 
gene loci.  These results indicated that Dot1l is required for maintaining normal 
HSCs and LICs that depend on MLL translocation proteins, and H3K79 



















The role of Dot1l in postnatal hematopoiesis 
 
Because of the close connection between Dot1l and MLL translocation 
leukemia, we examined the possible connection between Dot1l and normal 
hematopoiesis.  Given that the conventional Dot1l knockout mice are embryonic 
lethal, we generated conditional knockout mice from sperm obtained from the 
Knockout Mouse Project.    
 
Materials and Methods 
 
Generation of Dot1l conditional knockout mouse 
Sperms containing targeted Dot1l- allele (Figure 2.1) were obtained from 
the Knockout Mouse Project (CSD29070).  The targeted allele contained beta-
galactosidase (bgal) and neomycin resistance (neo) genes followed by polyA 
sequences for transcription termination in the intron 1-2 of the Dot1l locus.  This 
bgal-neo-polyA cassette is flanked by Flippase Recognition Target (FRT) 
sequences for sequence-specific recombination with Flippase (FLP).  In addition, 
exon 2 was flanked by loxp sequences for sequence-specific recombination with 
Cre protein.  The bgal-neo-polyA cassette is necessary for selection of mouse 
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embryonic stem cells that contains the Dot1l- allele for microinjection into 
recipient embryos.  Once the Dot1l- allele is correctly passed on, the selection 
cassette is removed by breeding with FLP positive transgenic mice (Jax 005703, 
Dot1lFallele, Figure 2.1).    The resulting mice were further bred to ubiquitously 
expressed CreER transgenic mice (Jax 004847) for Cre induction with tamoxifen 
in vivo and 4-hydroxytamoxifen (4-OHT) in vitro.  Induction of Cre recombinase 
removes exon 2 (Dot1l∆ allele, Figure 2.1) resulting in a frameshift mutation and a 
non-functional truncated protein.  Dot1lF/F;CreER+ mice were born in mendelian 
ratios and bred normally.  Genotype of animals was confirmed by genomic DNA 
extraction and PCR (Denville Scientific, DirectAmp kit, CG1100).  The strain 
background of all mice used was C57BL/6.  All mice used for experiments were 
between 6-10 weeks of age.  Genotyping primers and control and experimental 





Figure 2.1. Generation of conditional Dot1l knockout mice.   
Schematic of conditional Dot1l allele.  Dot1l- allele containing sperm were 
obtained from the Knockout Mice Project (KOMP, CSD29070).  Dot1l- mice were 
bred with FLP transgenic mice for the selection cassette removal (Dot1lF).  
Resulting mice were further bred with CreER transgenic mice for conditional 
Dot1l exon 2 excision (Dot1l∆) with tamoxifen injection or 4-OHT treatment.   
Loss of exon 2 (Dot1l∆) led to a frame shift mutation and resulted in a non-
functional product.  Genotyping PCR products were run on 1.5% agarose gels.  
PCR primers were designed for distinguishing Dot1lwt, Dot1l-, Dot1lF, and Dot1l∆ 
alleles.   
 
Genotyping Primers Dot1lwt Dot1l- Dot1lF Dot1l∆ 
F: GCCATGGTGTTTGTGTGTCCAGTT  




















For FLP allele (~750 bp) 
F: GCATTACCGGTCGATGCAACGAGTGATGAG 
R: GAGTGAACGAACCTGGTCGAAATCAGTGCG 
For Cre allele (~400 bp) 
 
Table 2.1. Genotyping primers.  Four different genotyping primer sets were used 
for distinguishing Dot1lwt, Dot1l-, Dot1lF, and Dot1l∆ alleles. 
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Control Dot1l+/+ Dot1lF/F;CreER- or Dot1lwt/wt;CreER+ (Dot1l+/+) 
Experimental Dot1lF/F Dot1lF/F;CreER+ (Dot1lF/F) 
 
Table 2.2. Control and experimental mice genotype designation.   
 
Dot1l excision  
Tamoxifen (Sigma T5648) was used in vivo for excision of Dot1l.  
Tamoxifen was dissolved in corn oil (Sigma C8267) at 10mg/ml stock solution 
and kept at 4oC for a month.  The stock was made fresh each month.  In order to 
minimize toxicity from tamoxifen, two doses of 100µg/g body weight were given 
one day apart (total 200µg/g body weight) via intraperitoneal (IP) injection.  4-
hydroxytamoxifen (4-OHT) (Sigma H7904), the active metabolite of tamoxifen, 
was used for excision of Dot1l in vitro.  4-OHT was dissolved in 100% EtOH at 
1mM stock solution and kept at -20oC.  Again, in order to minimize cell toxicity 
from prolonged 4-OHT exposure, cells were treated with 5nM of 4-OHT for three 
days and then moved to fresh growth media.   
 
Peripheral blood collection  
 Peripheral blood was collected via tail vein.  Animals were warmed with 
heat lamp (100 watt) and placed in mouse tail illuminator (Braintree Scientific, 
MTI).  Once tail veins on the sides were visible, a nick was made with razor blade 
and blood was collected by capillary action into EDTA coated tube (Ram 
Scientific 14-915-50).  The collected blood was used for genomic DNA extraction 
and PCR for checking Dot1l excision efficiency, complete blood count analysis 
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for monitoring hematopoiesis, and surface marker staining and flow cytometry for 
examining specific white blood cell population changes.   
 
 
Complete blood count (CBC) analysis 
 For CBC analysis, mice were given 200µg/g of tamoxifen every month for 
continued Dot1l excision and peripheral blood was collected from mice by tail 
vein bleed one week after each injection or when mice became moribund.  The 
samples were analyzed on Advia120 (Siemens) or Forcyte (Oxford Science) 
instruments.   
 
Competitive bone marrow transplantation 
 Competitive bone marrow transplantation involves transplanting wild type 
competitor cells with transgenic or knockout cells of interest into recipients that 
were lethally irradiated.  Lethal irradiation should remove recipient hematopoietic 
system.  This method is useful because competitive cells prevent animal death in 
case the genetically modified cells are unable to reconstitute recipient bone 
marrow, allowing detailed examination of hematopoietic compartment after 
transplantation.  Hence, it is important to distinguish competitor cells and residual 
long-lived recipient cells from genetically modified cells.  The distinction can be 
made by utilizing CD45 alleles.  CD45 protein is expressed on the cell surface of 
all nucleated hematopoietic cells (Hermiston et al., 2003).  The CD45 alleles are 
different between mouse strains, and C57BL/6 mice have the CD45.2 allele and 
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SJL/J mice have the CD45.1 allele (Komura et al., 1975).  Since this discovery, 
B6.SJL mice, which are C57BL/6 mice with CD45.1+ allele, have been generated 
(Shen et al., 1985).  Because the conditional Dot1l knockout mice generated 
were in C57BL/6 background and therefore CD45.2+, congenic CD45.1+ B6.SJL 
mice (Taconic Farms, 4007) were used as competitor cells and recipients.  
For competitive transplantation, CD45.2+ Dot1l+/+ or Dot1lF/F mice were 
injected with tamoxifen, and three days later bone marrow cells were harvested.  
Genomic DNA was extracted from 250,000-500,000 cells (Qiagen, DNeasy kit, 
69504) for checking Dot1l excision efficiency.  The cells were mixed with wild 
type CD45.1+ competitors at 1:1 or 3:1 ratio and transplanted into lethally 
irradiated (900 rad) CD45.1+ recipients.  Recipients were lethally irradiated (900 
rad) 2-4 hours before transplantation.   
 For examining cell-autonomous effects of Dot1l, bone marrow cells from 
CD45.2+ Dot1l+/+ or Dot1lF/F mice were harvested without tamoxifen injection.  
The cells were mixed with wild type CD45.1+ competitors at 1:1 ratio and 
transplanted into lethally irradiated recipients.  Recipients were injected with 
tamoxifen once bone marrow was stably reconstituted (8 weeks after 
transplantation).  CBC of recipients was checked before tamoxifen injection to 
ensure hematopoietic reconstitution. 
 
 
Flow Cytometry  
LSRII (BD Biosciences) was used for analysis of bone marrow and 
peripheral blood cells.  Antibodies were obtained from BD Pharmigen, 
 15 
eBioscience, or Biolegend (parenthesis indicates clone identification): anti-sca-1 
(D7), c-kit (2B8), CD48 (HM48-1), CD150 (mShad150), CD135 (A2F10), IL7Rα 
(A7R34), CD93 (AA4.1), CD41 (MWReg30), CD105 (MJ7/18), CD16/32 (93), 
CD45.1 (A20), CD45.2 (104), CD19 (6D5), B220 (30-F11), CD43 (ebioR2/60), 
IgM (RMM-1), CD11b (M1/70), Gr1 (R86-8C5), CD3 (145-2C11), CD4 (CK1.5), 
CD8α (53-6.7), TCRβ (H57-597), streptavidin-PE-TexasRed.  Lineage positive 
cells were defined by mouse lineage cocktail (BD Pharmigen 559971).   DAPI 
1µg/ml (Sigma D9542) was used for dead cell exclusion.  Standard buffer (1% 
FBS, 0.1% sodium azide, 1x PBS) was used for antibody staining.   Results were 
analyzed using FlowJo (TreeStar).   
 
Hematoxylin and Eosin (H & E) stain of bone marrow 
 Sternums of mice were fixed in 10% phosphate buffered formalin solution 
for 22-26 hours. H & E stain was performed by the University of Michigan Cancer 




Postnatal Dot1l deletion leads to pancytopenia 
First, we wanted to determine if the loss of Dot1l had adverse effects on 
the life expectancy of adult mice.  Dot1l was deleted from 6-10 week old mice 
utilizing a ubiquitously expressed CreER transgene activated by intraperitoneal 
(IP) tamoxifen injection (200µg/g body weight).  Efficiency of excision was 
checked by genotyping peripheral blood 1 week after tamoxifen injection.  
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Although high excision efficiency was initially observed, there was an increase of 
the non-excised allele when mice were re-genotyped between 4-5 weeks after 
the first tamoxifen injection.  In order to prevent cells with the non-excised allele 
from repopulating, mice were injected with tamoxifen every month, and 
peripheral blood was collected for genotyping and CBC analysis 1 week after 
each injection.   
Next, the loss of H3K79 methylation was confirmed by western blot of 
bone marrow cells 3 weeks after the excision (Figure 2.2) in order to verify that 
our mouse model indeed led to loss of Dot1l phenotype.  The loss of H3K79 
dimethylation (H3K79Me2) can be used as proxy for the loss of Dot1l and H3K79 
methylation since Dot1l is the only enzyme mediating H3K79 mono-, di-, and tri- 
methylation (Feng et al., 2010; Jones et al., 2008).  While mice were relatively 
healthy during the first two months, Dot1lF/F mice became moribund between 8 to 
12 weeks after the first tamoxifen injection (Figure 2.2).   
 
 
Figure 2.2. Prolonged loss of Dot1l in adult mice leads to death.  H3K79me2 
western blot of unfractionated bone marrow cells three weeks after Dot1l excision.  




CBC analysis of moribund mice showed that Dot1lF/F mice developed 
pancytopenia with mean white blood cell count of 2.2x103/µl, red blood cell count 
of 3.2x106/µl, and platelet count of 200x103/µl, while Dot1l+/+ mice had normal 
counts (Figure 2.3).  H & E staining of bone marrow from euthanized Dot1lF/F 
mice showed marked hypocellularity compared to control mice (Figure 2.4).  
These results showed that Dot1l is required for maintaining normal steady-state 
hematopoiesis. 
 
           
 
Figure 2.3.  CBC analysis.  Last CBC analysis before Dot1lF/F mice died or had to 





Figure 2.4. H & E stained section of bone marrow.  Dot1l deletion led to bone 
marrow hypocellularity in Dot1lF/F mice. Tissues were collected when Dot1lF/F 
mice became moribund.    
 
                
Dot1l deletion leads to depletion of phenotypic HSCs and progenitors 
Since pancytopenia after Dot1l deletion suggested failure of HSCs or 
multipotent progenitors, we examined the bone marrow progenitor cell 
populations by flow cytometry.   
First, HSC staining profile of Dot1lF/F;CreER- (Dot1l+/+), Dot1lwt/wt;CreER+ 
(Dot1l+/+), and Dot1lF/F;CreER+ (Dot1lF/F ) mice were examined in the absence of 
any treatment to exclude baseline differences between control and experimental 
animals (refer to Table 2.2).   All three genotypes showed similar staining profiles 
of HSCs (Figure 2.5). 
Once it was confirmed that there were no major baseline differences 
between the control and experimental genotypes, mice were injected with 
tamoxifen.  Three weeks after tamoxifen injection, mice were euthanized and 
bone marrow cells were harvested for population analysis.  A three week point 
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was chosen based on the observation that by 4-5 weeks post-injection, the few 
cells that escaped excision competed out the rest of bone marrow.   
The harvested bone marrow cells were stained with antibodies for cell 
surface markers to identify HSCs and progenitors.  Frequency of population was 
calculated based on the total live cell count from each sample obtained from the 
flow cytometer.  Live cells were defined by first gating out red blood cells and 
DAPI positive dead cells, and then selecting singlet cells and correct size.   The 
definition of each population was immunophenotypically characterized in previous 
studies (Kiel et al., 2005; Maillard et al., 2009; Pronk et al., 2007).  HSC: lineage-, 
sca1+, ckit+, CD48-, CD150+.  Common lymphoid progenitors (CLP): lineage-, 
IL7Rα+, sca1lo, ckitlo, AA4.1+, CD135+.   Megakaryocyte progenitors (MkP): 
lineage-, sca1lo, ckit+, CD150+, CD41+.  Erythroid progenitors (EryP): lineage-, 
sca1lo, ckit+, CD41-, CD16/32-, CD105+.  Granulocyte macrophage progenitors 
(GMP): lineage-, sca1lo, ckit+, CD41-, CD16/32+, CD105-. 
The frequencies of HSCs and progenitors were all significantly decreased 
in Dot1l-deficient bone marrow compared to control (Figures 2.6 and 2.7). The 
decrease in frequency was particularly pronounced for HSCs.  These results 
indicated that Dot1l is required for the maintenance of HSCs and lineage specific 







Figure 2.5. Baseline comparison of HSCs in mice lines.  Bone marrow cells of 
Dot1lF/F;CreER-, Dot1lwt/wt;CreER+ and Dot1lF/F;CreER+ mice were stained for 
HSCs (lineage-, sca1+, ckit+, CD48-, CD150+).  In the absence of tamoxifen 
injection, all three mice lines showed similar HSC staining profiles.  Percentages 







Figure 2.6.   Deletion of 
Dot1l led to loss of HSCs 
and progenitors.  (A) 
Staining profile of HSCs and 
progenitors 3 weeks after 
tamoxifen injection in 
Dot1l+/+ and Dot1lF/F mice.   
 
HSC: lineage-, sca1+, ckit+, 
CD48-, CD150+.   
 
CLP: lineage-, IL7Rα+, 
sca1lo, ckitlo, AA4.1+, 
CD135+.    
 
MkP: lineage-, sca1lo, ckit+, 
CD150+, CD41+.   
 
GMP: lineage-, sca1lo, ckit+, 
CD41-, CD16/32+, CD105-. 
 
EryP: lineage-, sca1lo, ckit+, 
CD41-, CD16/32-, CD105+.  
 
Percentages are based on 
total live cell count. 
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Figure 2.7. Bar graph of population frequencies as defined in Figure 2.6.  Dot1l 
deletion led to a statistically significant decrease in HSCs and progenitors in all 
three lineages.  Percentages are based on total live cell count.  Data represent 





Dot1l deletion leads to depletion of functional HSCs 
In order to rule out the persistence of functional HSCs with altered cell 
surface markers, we performed competitive bone marrow transplantation 
experiments.  The origin of cells can be traced by utilizing two different CD45 
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alleles.  Recipient and competitive donor cells have CD45.1 allele, while control 
and experimental donor cells have CD45.2 allele.  Relative contribution of the 
donor cells in reconstituting the bone marrow can be examined by staining for 
CD45 expressing peripheral leukocytes.  Dot1l+/+ or Dot1lF/F mice (CD45.2+) 
were injected with tamoxifen and bone marrow were harvested three days later.  
These cells were mixed with competitor cells (CD45.1+) at 1:1 or 3:1 ratio and 


















Figure 2.8.  Schematic of competitive bone marrow transplantation experiment.  
CD45.2+ Dot1l+/+ or Dot1lF/F mice were injected with tamoxifen and bone marrow 
cells were harvested and mixed with CD45.1+ competitors at 1:1 or 3:1 ratio.  
The mixture was transplanted into lethally irradiated CD45.1+ recipient. 
 
Contribution of CD45.2+ cells were examined in myeloid, B lymphoid, and 
T lymphoid lineages (Figure 2.9).  Peripheral blood was collected on indicated 
weeks after transplantation.  There were markedly decreased contributions of 
Dot1lF/F CD45.2+ cells to the myeloid, B lymphoid, and T lymphoid lineages at all 




       
 
Figure 2.9. Bar graph of CD45.2+ cells in peripheral blood. Peripheral blood was 
stained for myeloid (Gr1+, CD11b+), B lymphoid (B220+, CD19+), and T 
lymphoid (CD3+) cells.  Blood was collected from recipients on indicated weeks 
after transplantation.  Dot1lF/F cells minimally constituted recipient peripheral 
blood.  Data represent mean and standard deviation.   
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Bone marrow and thymus were harvested 16 weeks after transplantation 
and were similarly examined for contribution of CD45.2+ cells into the HSC, 
myeloid, B lymphoid, and developing T lymphoid compartments.  Even at a 3:1 
ratio, Dot1lF/F CD45.2+ cells minimally contributed to recipients’ hematopoietic 
system (Figures 2.10 and 2.11).  These results showed that Dot1l is required for 
functional HSC activity.   
        
 
 
Figure 2.10.  Bar graph of CD45.2+ cells in recipient bone marrow and thymus 16 
weeks after transplantation.  Cells were stained for HSCs (lineage-, sca1+, ckit+, 
CD48-, CD150+), myeloid (Gr1+, CD11b+), B lymphoid (B220+, CD19+) and 
developing T cells (CD4+, CD8+).  Even at 3:1 ratio, Dot1lF/F cells failed to 
reconstitute recipient hematopoietic system.  Data represent mean and standard 
deviation. 
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Figure 2.11.  Staining profile of recipient HSCs (lineage-, sca1+, ckit+, CD48-, 
CD150+) 16 weeks after transplantation.  Percentages are based on HSC gate.   









Defect of HSCs after Dot1l deletion is cell-autonomous 
 After observing defects in Dot1l lacking HSCs, we examined if these 
defects were mediated in a cell-autonomous manner.  Given that our mouse 
model led to excision of Dot1l from all cells through the ubiquitously expressed 
CreER, it is necessary to distinguish if the defects in HSCs are due to HSCs 
themselves or due to defects in stroma.   
In order to study this, mixed bone marrow transplantation was performed 
without prior tamoxifen injection. CD45.2+ Dot1l+/+ or Dot1lF/F bone marrow cells 
were transplanted with wild type CD45.1+ competitive cells at 1:1 ratio into 
lethally irradiated (900 rad) congenic CD45.1+ recipients.  This created a 
condition in which Dot1l could be inactivated only in the donor-derived cohort of 
CD45.2+ cells in the presence of wild-type competitors and in a wild-type 
microenvironment.  After measuring CD45.1/2 chimerism 8 weeks after 
transplantation, recipient mice were injected with tamoxifen (Figure 2.12).   
Peripheral blood was collected on indicated weeks after the tamoxifen injection to 
assess changes in CD45.1/2 chimerism.  If the defects of Dot1l lacking HSCs 
were cell autonomous, contribution of Dot1lF/F CD45.2+ cells will decrease in 
peripheral blood, while if the HSC defects were due to stroma defects, Dot1lF/F 
CD45.2+ cells will continue to function in wild type stroma environment.   
Injection of tamoxifen led to the rapid loss of CD45.2+ cells in all three 
lineages examined (Figure 2.13), indicating that defects in Dot1l lacking HSCs 
were cell-autonomous.  The loss was particularly rapid and pronounced for the 
short-lived myeloid cells, which became profoundly depleted only two weeks after 
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tamoxifen injection.  Examination of bone marrow HSCs, myeloid cells, B cells, 
and thymic T cells 16 weeks after the tamoxifen injection showed minimal 
contribution from Dot1lF/F CD45.2+ cells (Figure 2.14).  These results showed 
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Figure 2.12.  Schematic of bone marrow transplantation experiment for 
examining cell-autonomous HSC defect.  CD45.2+ Dot1l+/+ or Dot1lF/F cells and 
CD45.1+ competitors were mixed at 1:1 ratio and transplanted into lethally 
irradiated (900 rad) CD45.1+ recipients. Once bone marrow was reconstituted 8 






















Figure 2.13. HSC defects in Dot1l-
deficient cells are cell-autonomous.  
Recipients were transplanted as 
described on Figure 2.11. Blood was 
collected from recipients on indicated 
weeks after tamoxifen injection, and 
stained with cell surface markers for 
myeloid, B lymphoid, and T lymphoid.   .  
After the Dot1l excision, Dot1lF/F cells 
rapidly disappeared from peripheral 
blood.  Data represent mean and 
standard deviation 
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Figure 2.14. Bar graph of bone marrow and thymus reconstitution by CD45.2+ 
cells 16 weeks after tamoxifen injection.  Dot1lF/F cells minimally remained in the 










The role of Dot1l in MLL fusion protein-mediated leukemogenesis 
 
Because of the previous connection between Dot1l and MLL translocation 
leukemia, we examined further the role of Dot1l in MLL fusion protein-mediated 
leukemogenesis.  Studies show a strong correlation between H3K4 methylation 
marks by MLL and H3K79 methylation marks by Dot1l at important MLL fusion 
protein downstream target loci (Krivtsov et al., 2008).  This correlation has 
functional consequences since the loss of H3K79 methylation at target gene loci 
leads to decreased expression (Krivtsov et al., 2008; Monroe et al., 2010).  
Furthermore, loss of MLL fusion protein by conditional MLL-ENL-ER leads to 
decreased H3K79 methylation in the target gene loci (Milne et al., 2005).  Our 
studies in normal HSCs also showed that Dot1l was required for stem cells, and 
we wanted to know if Dot1l is required for leukemia initiating cells (LICs) as well.  
Based on these studies, we examined in detail if Dot1l is required for MLL 
translocation leukemia and if this requirement for leukemia is universal or limited 





Materials and Methods 
 
Dot1l excision 
For in vitro experiments, 4-OHT (Sigma H7904) was used for Dot1l 
excision.  4-OHT was dissolved in 100% ethanol (EtOH) at 1mM stock solution, 
and equivalent volume of EtOH was used as control for 4-OHT treatment.   
Cell culture  
 All cells were cultured in Iscove’s Modified Dulbecco’s Medium (Invitrogen 
12440061) with 10ng/ml of IL3 (R & D Systems) and 1% penicillin/ streptomycin 
(P/S, Invitrogen 15140122).  For cells with neomycin resistance gene, 1mg/ml 
G418 (Invitrogen 10131035) was added.    
 
Plasmids, Retroviral Transductions and CFU Assay 
Plasmids used for retrovirus generation were based on the Murine Stem 
Cell Virus (MSCV) vector (Clontech) derived from the murine embryonic stem cell 
virus (Grez et al., 1990; Hawley et al., 1994).   The MSCVneo vector has a 
neomycin resistance gene, and the MigR1 vector has an internal ribosomal entry 
site followed by the GFP coding sequence for selection of transduced cells with 
either G418 or GFP, respectively.  Retroviruses were generated by transfecting 
MigR1-MLL-AF9, MigR1-E2A-HLF, MigR1-Hoxa9, MigR1-Meis1, MSCVneo-HA-
Dot1l or methyltransferase mutant Dot1l constructs (Kroon et al., 1998; Monroe 
et al., 2010; Muntean et al., 2008; Okada et al., 2005) into Plat-E cell line (Morita 
et al., 2000) with Fugene 6 (Roche).  Fresh viral supernatants were used for all 
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experiments.  Bone marrow cells were isolated from 6-8 week old mice 4 days 
after 150µg/g 5-fluoruracil (5-FU, Sigma) injection.  5-FU injection kills more 
differentiated bone marrow cells that go through cell division while low-cycling 
stem cells are minimally affected (Kopp et al., 2005).  Hence, injection with 5-FU 
enriches for stem cells when harvesting bone marrow.  Bone marrow cells were 
collected by flushing the femur and tibia with IMDM media (Invitrogen) with 1% 
P/S and 2% FBS (Stemcell Technologies) in a 27.5G needle.  The harvested 
cells were placed overnight in 1% P/S, 10ng/ml IL3, IL6, and 100ng/ml SCF (R & 
D Systems), 15% FBS (Stemcell Technologies), and IMDM media (Invitrogen).  
Leaving the cells overnight in culture allows more differentiated cells to attach to 
flask and further enrich for stem cells in the supernatant.  The cells were 
transduced twice with retrovirus by spinoculation at 3200 rpm for 90 minutes at 
room temperature.  2-3 days later, transduced cells were plated in Methocult 
media (Stem Cell Technologies, M3234) with 1% P/S, 10ng/ml IL3, IL6, GM-
CSF, 100ng/ml SCF, 5nM 4-OHT or EtOH, and 1mg/ml G418 (Invitrogen 
10131035).  Colonies were scored 7-10 days after plating for three rounds.  In 
the final round, colonies were stained with 0.1% p-iodonitrotetrazolium violet (INT, 
Sigma, 58030) for visualization.   
 
Cell Growth, Cell Cycle, and Apoptosis Assays 
 Cell growth was assessed by the CellTiter-Glo assay (Promega G7572).  The 
assay quantifies ATP levels in cell culture, which is a proxy for metabolically 
active live cells.  Cells were treated with either 4-OHT or EtOH as control for 
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three days for the excision of Dot1l, and CellTiter-Glo assay was performed 
every day per manufacturer’s instructions.  Luminescence was measured by M5 
microplate reader (Molecular Devices).   
 Similarly, 4 days after treatment with 4-OHT or ethanol, cells were incubated 
with 10ng/ml propidium iodide (Invitrogen P3566) and 100ng/ml RNase A (5 
Prime 2500130) in standard buffer for 30 minutes at 37oC for cell cycle analysis 
or stained with 1µg/ml DAPI (Sigma 9542) and Annexin V-APC (eBiosciences 
BMS306APC/100) in Annexin V Binding Buffer (Biolegend 422201) for 15 
minutes at room temperature for apoptosis assay.  Samples were run on LSRII 
(BD biosciences) and analyzed with Flowjo (Treestar).   
 
RNA extraction, cDNA generation, and Quantitative PCR (qPCR) 
RNA was extracted from cells after 4 days of 4-OHT or EtOH treatment 
using TRIzol Reagent (Invitrogen 15596026) and isopropanol precipitation.  RNA 
was quantified with an Ultraspec 2100 (GE Healthcare) and 2-4 µg of RNA was 
converted to cDNA using SuperScript II (Invitrogen 18064022) according to the 
manufacturer’s instructions.   For qPCR reaction, SYBR (4367659) and Taqman 
mastermix (4304437) were used for duplex DNA and Fam fluorophore detection, 
respectively.  An ABI7500 machine was used for reading qPCR plates.   
 
Gene Detector Primers 
5S rRNA SYBR F: TCTACGGCCATACCACCCTGA 
R: GCCTACAGCACCCGGTATTCC 
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HA-Dot1l SYBR F: GCCACCATGTACCCCTACGACGTG 
R: GATTTCCTCGCAGACCCACCGGAT 
Hoxa9 Fam Applied Biosystems (Mm00439364_m1) 
Meis1 Fam Applied Biosystems (Mm00487664_m1) 
 
Table 3.1 qPCR primers. 
 
 
Protein extraction and Western blot 
Whole cell lysate samples were prepared by directly resuspending 
500,000 cells in 100µl of Tris-Glycine SDS Sample Buffer (Novex LC2676) with 
10% beta-mercaptoethanol (Sigma).  Samples were then sonicated for 15 
minutes (Bioruptor, Diagenode) and incubated at 95oC for 5 minutes.  Samples 





The MLL-AF9 oncogene requires Dot1l for transformation 
Since the loss of Dot1l led to the loss of normal HSCs, we examined if 
LICs were also generally lost with Dot1l excision.  Because Dot1l has been 
implicated in leukemia with MLL translocation, we wanted to know if the potential 
anti-leukemic effects of Dot1l loss are limited to MLL translocation alone or 
applicable to leukemia with other molecular signatures.  Hence, we chose three 
different oncogenes and examined if Dot1l-deficient bone marrow cells could be 
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transformed.  We selected MLL-AF9, an MLL translocation oncogene, 
Hoxa9/Meis1 proteins which are downstream targets of MLL translocation, and 
E2A-HLF, an oncogene unrelated to MLL translocation, for examination of 
transformation by colony forming unit (CFU) assay.   CFU assay results are 
closely correlated with leukemogenesis in vivo (Lavau et al., 1997), and are a 
useful tool for studying leukemogenesis in vitro.   
Bone marrow cells were harvested after 5-fluorouracil (5-FU) injection for 
HSC enrichment, transduced with oncogenes or MigR1 vector control, and plated 
on methylcellulose media in the presence of either 4-OHT for Dot1l excision or 
EtOH  as control.  Cells were replated every 7-10 days for three rounds and 






1st 2nd 3rd CFU
 
 
Figure 3.1.  Schematic of colony forming unit (CFU) assay. 
 
 
After the second round, cells were harvested and genomic DNA was 
extracted for checking excision efficiency.  Genotyping showed high efficiency of 
Dot1l excision with 4-OHT treatment (Figure 3.2).  There was some baseline 
excision occurring in Dot1lF/F cells treated with EtOH.  However, these cells were 
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still able to form colonies (Figure 3.3) and H3K79 methylation was present in 
comparable levels to Dot1l+/+ cells (Figure 3.7).     
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Figure 3.2.  Genotyping of transduced cells after the second round.  PCR 
reaction showed high excision efficiency with 4-OHT treatment in all cells.  There 
was baseline excision (Dot1l∆ allele in 4-OHT untreated cells), but this did not 
interfere with experiments. 
 
While Hoxa9/Meis1 and E2A-HLF transformed cells were able to form 
colonies even upon Dot1l excision, MLL-AF9 transformed cells were unable to 
form colonies (Figures 3.3 and 3.4).  MLL-AF9 transformed cells with 4-OHT 
treatment had colony counts on par with MigR1 control (3.4), and whole plate 
examination with INT dye showed very few staining colonies (3.3).  Even after 
being grown in liquid culture for more than 8 weeks, MLL-AF9 transformed cells 
continued to require Dot1l for colony formation (Figures 3.5 and 3.6).  These 
results suggested that Dot1l is selectively required for oncogenic transformation 





Figure 3.3. Colony formation on methocult plates.  Dot1lF/F MLL-AF9 cells treated 













                
Figure 3.4.  Bar graph of colony count at final round.  Data represent mean and 
standard deviation.  Dot1l is required for transformation by MLL-AF9 but not by 
Hoxa9/Meis1 and E2A-HLF 
 
                 
 
Figure 3.5.  Bar graph of colony count with cells grown in liquid culture for >8 
weeks.  Dot1lF/F MLL-AF9 cells treated with 4-OHT failed to form colonies even 
after established transformation.  Data represent mean and standard deviation.   
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Figure 3.6.  Colony formation on methocult plates.  Dot1l is required for colony 















Dot1l deletion leads to a cell cycle defect in MLL-AF9 transduced cells 
We further examined the consequences of Dot1l loss in MLL-AF9 
transformed cells in liquid culture.  First, we confirmed that H3K79 methylation 
was abolished with Dot1l excision.  Western blot after 4-OHT treatment of cells 
showed that H3K79me2 was comparably lost among all Dot1lF/F cell lines. 
 
  
     
    
 
Figure 3.7.  H3K79me2 western blot of Hoxa9/Meis1, E2A-HLF, and MLL-AF9 
transformed cells.  H3K79me2 western blot showed loss of methylation with 4-
OHT treatment in all Dot1lF/F cell lines.  Protein was harvested 4 days after EtOH 
or 4-OHT treatment.  Histone 3 blot was used as loading control. 
 
 
Next, we examined cell growth in liquid culture.  Cells were treated with 4-
OHT or EtOH for three days, and then moved to regular growth media. Cell 
toxicity was observed with prolonged culture in 4-OHT, and by day three Dot1l 
was reliably excised.  In accordance with the CFU assay results, MLL-AF9 cells 
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stopped growing in liquid culture with 4-OHT treatment while Hoxa9/Meis1 and 
E2A-HLF cells continued to grow (Figure 3.8.).  Cell growth was assessed with 
the CellTiter-Glo assay, which measures ATP levels and hence metabolically 
active live cells.  The CellTiter-Glo assay was particularly useful compared to 
trypan blue staining and manual counting due to increased lightly staining cells, 
dead cells and debris.  Also, technical and biological replicates were easy to 
obtain with the CellTiter-Glo assay, making the data more reliable.   
 
         
Figure 3.8.  Loss of Dot1l leads to growth impairment for MLL-AF9 transformed 
cells but not for Hoxa9/Meis1 or E2A-HLF transformed cells.  Cells were grown in 
culture for more than 8 weeks.  Cell growth was measured by CellTiter-Glow 
assay with either ethanol (EtOH) as control or 4-OHT treatment for Dot1l excision.  
All values were normalized to day 1.  Data represent mean and standard 
deviation.   
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Based on the liquid culture cell growth data, we picked several time points 
for examining the phenotype of Dot1l loss in more detail.  First, the cell cycle was 
assessed using propidium iodide staining 1, 2, 3, and 4 days after 4-OHT 
treatment (Days 2, 3, 4, and 5 on growth curves) to identify the best time frame 
for further study.  Propidium iodide is a DNA intercalating agent that can be used 
to quantify cell DNA content and hence its cell cycle stage (Crissman et al., 
1976).     
Cell cycle analysis using propidium iodide showed that there was a 
marked increase in G0-G1 phase in MLL-AF9 cells after Dot1l excision, while this 
effect was not present in Hoxa9/Meis1 or E2A-HLF cells (Figure 3.9 and 3.10).  
This suggested G1/S cell cycle arrest as the primary mechanism for decreased 
cell growth in MLL-AF9 cells.  These data corroborate normal yolk sac cell data 
that show increases in G0-G1 as well (Feng et al., 2010) but are somewhat 
different from the embryonic stem cell data (Jones et al., 2008) that show 
increases in G2 phase.  This difference in result is most likely due to different cell 
types.  
The extent of G0-G1 block was greatest for MLL-AF9 transformed cells 4 
days after treatment with 4-OHT.  Further time points were not examined 
because cell splitting was necessary for some cell types, which might affect cell 
growth rate.  From these data, day 4 was chosen for subsequent studies 





Figure 3.9.  Time course of cell cycle analysis.              EtOH                      4-OHT  
Cells were treated with 4-OHT for Dot1l excision or EtOH and 3 days later moved 
to regular growth media.  Propidium iodide staining was performed every day for 




Figure 3.10.  Quantification of cell cycle.  Cells were stained with propidium 
iodide 4 days after EtOH or 4-OHT treatment.  Values shown are ratio of 4-OHT 
treatment over EtOH treatment for respective cell lines.  Dot1lF/F MLL-AF9 cell 
line showed increase in G0-G1 and decrease in S and G2-M phases with 4-OHT 
treatment.  Data represent mean and standard deviation.   
 
We then examined apoptosis of cells with Dot1l excision.  From previous 
reports (Chang et al., 2010; Feng et al., 2010; Jones et al., 2008) we expected to 
see an increase in apoptosis.  However, we noticed an increase in apoptosis 
from 4-OHT treatment alone for MLL-AF9 transformed cells and variably in E2A-
HLF cells (Figure 3.11).  Notably, this effect was most prominent in MLL-AF9 
transformed cells in both Dot1F/F and Dot1l+/+ cell lines compared to E2A-HLF 
and Hoxa9/Meis1 transformed cells.  While the cause of the 4-OHT effect is not 
clear, it should be noted for future experimental designs that MLL translocation-







Figure 3.11.  Annexin V staining of cell lines after Dot1l excision.  There was 
almost doubling of Annexin V positive cells after 4-OHT treatment of MLL-AF9 
transformed cells.  For E2A-HLF cells the increase ranged from 25-40%.  
Hoxa9/Meis1 transformed cells were least affected.   
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The 4-OHT effect was taken into account by dividing the 4-OHT treatment 
over the EtOH treatment and comparing Dot1l+/+ with Dot1lF/F.  The resulting 
ratios showed that there was no consistent change in apoptosis rate measured 
by annexin V staining (Figure 3.12).  
 
         
Figure 3.12.  Annexin V staining for apoptosis assay.  Cells were stained with 
annexin V 4 days after EtOH or 4-OHT treatment. Values shown are ratio of 4-
OHT treatment over EtOH treatment for respective cell lines.  There was no 
statistically significant change in apoptosis with Dot1l excision.  Data represent 
mean and standard deviation.   
 
We also examined if the expression of downstream targets of MLL-AF9 protein 
were affected by the loss of Dot1l.  As reported from previous studies (Krivtsov et 
al., 2008; Monroe et al., 2010), qPCR showed loss of Dot1l in MLL-AF9 cells led 
to decreased expression of Hoxa9 and Meis1 (Figure 3.13), which are crucial for 
MLL translocation-mediated leukemia (Ayton and Cleary, 2003; Zeisig et al., 
2004).  Minimal changes in the gene expressions were noted in cells transformed 
by Hoxa9/Meis1 and E2A-HLF probably due to exogenous promoter driven 
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expression in Hoxa9/Meis1 cells and the already very low expression of Hoxa9 in 
E2A-HLF cells (E2A-HLF cells did not express detectable Meis1).  In contrast, 
house-keeping genes such as Beta actin and Gapdh showed relatively stable 
expressions with Dot1l excision (Figure 3.13).  These results showed that the 
loss of Dot1l in cells with MLL-AF9 led to cell cycle arrest and downregulation of 
key downstream targets, leading to failure of oncogenic transformation.    
           
 
 
Figure 3.13.  The loss of Dot1l leads to selective loss of critical downstream 
target gene expression in MLL-AF9 transformed cells.  qPCR of Hoxa9, Meis1, 
and house keeping genes Beta actin and Gapdh expressions.  Samples were 
collected 4 days after EtOH or 4-OHT treatment.  Values were normalized to 5s 
rRNA internal control and EtOH treatment for respective cell lines.  Data 
represent mean and standard deviation.   
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H3K79 methylation is required for transformation by MLL-AF9 oncogene 
We then tried to identify the region of Dot1l that is necessary for 
transformation by MLL-AF9.  The N-terminal 1-416 residues of Dot1l are 
sufficient for histone methyltransferase (HMT) activity (Min et al., 2003), while 
827-1095 residues of Dot1l are important for interaction with MLL translocation 
partners and transcriptional elongation proteins (Mueller et al., 2009).   In order to 
potentially distinguish the function of HMT versus protein interaction by Dot1l, we 
made HA-tagged constructs of Dot1l with point mutations or Dot1l fragments 
(Figure 3.14).  The full-length wild type Dot1l construct was courtesy of Dr. 
Robert Slany (University of Erlangen).   RCR is a full-length Dot1l construct with 
GSG to RCR mutation in the S-adenosylmethionine binding domain that lacks 
enzymatic activity (Min et al., 2003; Okada et al., 2005).  Residues 1-416 of Dot1l 


















Figure 3.14.  Schematic of Dot1l constructs.  Wild type, HMT inactive (RCR) and 
HMT domain alone were used to determine if HMT activity of Dot1l is required for 





We introduced these HA-tagged Dot1l constructs into Dot1l-deficient MLL-
AF9 cells, and repeated the methocult CFU assay (Figure 3.1).  Endogenous 
Dot1l excision was confirmed by PCR after the second round (Figure 3.15) and 
showed high efficiency of excision.  The expression of exogenous Dot1l was 
confirmed by qPCR of HA tag sequences (primers in Table 3.1) compared to the 
neomycin vector control (Figure 3.16).   
 
 
               
 
Figure 3.15.  Genotyping of transduced cells after the second round.  PCR 
reaction showed high excision efficiency of endogenous Dot1l with 4-OHT 
treatment in all cells.   
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Figure 3.16.  qPCR of exogenous Dot1l expression.  All constructs show 
expression compared to Neo vector alone.  Values were normalized to 5s rRNA 
internal control.  Data represent mean and standard deviation.   
 
 
Restoration of H3K79 methylation with construct expression was 
confirmed by western blot (Figure 3.17).  Wild type HA-Dot1l was able to restore 
H3K79 methylation, but the HMT domain alone failed to do so.  This result is in 
contrast to the many in vitro HMT assays where the HMT fragment was sufficient 
for H3K79 methylation of chromatin substrates (Feng et al., 2002; Min et al., 
2003).   Furthermore, Dot1l has a KKGR nuclear localization sequence identical 
to its yeast homologue (San-Segundo and Roeder, 2000) at residues 400-403, 
and hence the HMT construct (1-416) should enter the nucleus.  Therefore, the 
inactivity of the HMT domain in vivo was somewhat unexpected.  However, it is 
possible that for in vivo methylation, protein interactions are necessary for 





   
 
Figure 3.17. Western blot of H3K79me2 after second round.  Western blot 
showed restoration of H3K79Me2 with the introduction of exogenous wild type 





Because of lack of methylation activity by the HMT construct in vivo, it was 
excluded from further studies.  CFU assays showed that the RCR construct failed 
to rescue CFU loss after Dot1l deletion in MLL-AF9 cells, while the exogenous 
wild type Dot1l restored CFU formation (Figures 3.18 and 3.19).  Because RCR 
is a full-length Dot1l construct, protein interaction should be intact even though it 
is catalytically inactive.  These results suggested that H3K79 methylation is 
required for transformation by MLL-AF9, and protein interactions without HMT 
activity could not rescue CFU formation.   
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Figure 3.18.  Colony formation on methocult plates.  4-OHT treated Dot1lF/F MLL-
AF9 cells with wild type Dot1l were able to form colonies, but not those with RCR. 
INT stain of plates at final round.  
 
 
                        
 
Figure 3.19.  Bar graph of colony count at final round.  Data represent mean and 
standard deviation.   
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Chapter IV 




Expression of Dot1l in embryos has been examined using a constitutive 
Dot1l knockout mouse line.  Utilizing the beta-galactosidase gene, E9.5 embryos 
have been stained with X-gal and are shown to be constitutively expressed 
(Jones et al., 2008).  However, there has been no examination of adult 
mammalian tissues for Dot1l expression.   
Since CreER is ubiquitously expressed, we examined the major organs of 
mice after Dot1l excision with immunohistochemistry.  We used H3K79me2 mark 
as the proxy for Dot1l expression because the antibody works very well.  In 
addition, if complete loss of H3K79me2 was observed with Dot1l excision, it 
would corroborate that Dot1l is the only H3K79 methyltransferase.    Necropsy 
was performed on moribund Dot1lF/F mice (Figure 2.2), and tissues from Dot1l+/+ 
mice were collected once all Dot1lF/F mice were euthanized.     
 
Materials and Methods 
 






Tissues were collected and immediately placed in 10% phosphate 
buffered formalin solution for fixation (Fisher SF100-4).  Tissues were fixed for 
22-26 hours and then placed in 70% ethanol solution for stopping over fixation.  
Fixed tissues were paraffin embedded, sectioned, and stained at the University 
of Michigan Cancer Center Tissue Core. 
 
H3K79me2 immunohistochemial staining 
Immunohistochemical staining was performed on the DAKO Autostainer 
(DAKO) using biotinylated goat anti-Rabbit IgG (Invitrogen, 1:250), streptavidin-
HRP and diaminobenzidine as the chromogen. De-paraffinized sections of 
mouse formalin fixed tissue at five-micron thickness were labeled with anti-
H3K79me2 antibody (Rabbit polyclonal antibody, 1:1500, ab3594, 30 minutes) 
after microwave citric acid epitope retrieval. Appropriate negative (no primary 
antibody) and positive controls (normal human liver) were stained in parallel with 




H3K79me2 immunohistochemistry of conditional Dot1l knockout mice 
Tissues were collected for H3K79me2 immunohistochemistry to confirm 
Dot1l deletion and to examine the tissue structure (Figure 4.1).   In general, mice 
did not show gross abnormalities of organs except for the atrophy of 
seminiferous tubules.  However, as evident Figure 4.1, foci of spermatogenesis 
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were observed though at decreased numbers.   Most major organ tissues 
showed clear loss of H3K79me2 with loss of Dot1l.  The exception was brain 
tissue, which showed remaining H3K79me2.  Initially, we considered that the 
blood-brain barrier might hinder tamoxifen entry to the brain and hence decrease 
excision efficiency.  However, presentations by Dr. Lieberman’s lab (University of 
Michigan) using the same CreER mice showed clear excision of a floxed gene in 
brain tissue.  Currently, we do not have a clear explanation for the discrepancy.  
It may be that for brain cells a higher tamoxifen concentration is required as we 
used less tamoxifen than the Lieberman lab for excision.  More interestingly, 
neurons and glial cells may have special regulation preventing the loss of H3K79 
methylation or there may be another H3K79 methyltransferase active only in the 
brain that can compensate the loss of Dot1l.    
With the exception of brain, which showed remaining H3K79 methylation, 
most organs showed relatively normal histology despite the clear loss of 
H3K79me2 compared to bone marrow H & E sections (Figure 2.4).  These 
results suggested that hematopoietic toxicity is the major consequence of Dot1l 
excision in our mouse model system.   
















Figure 4.1.  H3K79me2 immunohistochemical staining of representative Dot1l+/+ 
and Dot1lF/F tissue sections.  Tissues were collected when Dot1lF/F mice became 
moribund after long-term Dot1l excision (Figure 2.2).  With the exception of brain 
tissue, most major organs showed complete loss of H3K79me2 with Dot1l 









Other Experiments and Preliminary Results: Expression Analysis of HSCs 
 
 Given our results regarding the role of Dot1l in normal hematopoiesis and 
leukemogenesis, we designed further experiments to address additional 
questions raised from these studies.  A most interesting question remains that 
normal HSCs and MLL-AF9 LICs require proper Dot1l expression while 
Hoxa9/Meis1 and E2A-HLF LICs do not.  Previous studies with embryonic stem 
cells and Dot1l knock down show that relatively small set of genes are changed 
with Dot1l loss (Barry et al., 2009).  In order to identify potential effectors of Dot1l, 
we performed a microarray analysis on immunopurified HSCs after Dot1l 
excision.   
 
 
Materials and Methods 
 
HSC sorting and RNA extraction 
 6-10 week old mice were injected with tamoxifen 200µg/g weight by IP 
injection and euthanized 1 week later.  HSC was immunophenotypically defined 
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as in Figure 2.5 and sorted using FACSAria (BD Biosciences).  Cells were 
collected directly into pre-chilled TRIzol reagent.  After chloroform extraction, the 
aqueous phase was mixed with an equal volume of 70% ethanol.  The mixture 
was loaded onto an RNeasy MinElute column, DNase I treated, and the RNeasy 
micro kit protocol was followed (Qiagen 74004).   
 
Amplification, cDNA conversion, biotin labeling and fragmentation 
 Total RNA from HSC was amplified using Ovation Pico WTA system 
(Nugen 3300), converted into double stranded cDNA using WT-Ovation Exon 
Module (Nugen 2000), biotin labeled and fragmented using Encore Biotin Module 
(Nugen 4200).  Fragmented cDNA was hybridized on Mouse Gene ST 1.0 array 
(Affymetrix) by University of Michigan Microarray Core Facility.   
 
Bioinformatics Analysis 
 Data from Microarray Core Facility included a list of genes with over 2 fold 
change and P-values.  The list was further analyzed by first removing duplicate 
probes, and taking a cut off at P=0.05 for Cluster 3.0 (Stanford University) or 
P=0.2 for Gene Set Enrichment Analysis (GSEA, Broad Institute) programs.  
Cluster 3.0 program was used for heat map generation and was visualized with 
TreeView (Stanford University).  Running the GSEAPreRanked program grouped 
genes in similar pathways together.  The P-value cut off was less stringent for 
GSEA to allow inclusion of more genes for a particular pathway, which increased 
the possibility that a given pathway is a true positive.      
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EasySep Purification system 
 In order to quickly assess phenotypic difference between progenitors 
versus differentiated cells, EasySep Mouse Hematopoietic Progenitor Cell 
Enrichment kit (Stem Cell Technology 19756) was used according to 
manufacturer’s instructions.  The kit utilizes magnetic separation based on 
lineage markers and biotin-streptavidin interaction.  Because it is a negative 
selection, the resulting purified cells could be used without possible confounding 





Loss of H3K79 methylation upregulates differentiation promoting genes 
and polycomb target genes in HSCs 
 First we tried to pick the best time to collect HSCs after Dot1l excision.  
Given that by 3 weeks the vast majority of the HSCs were gone (Figure 2.6), we 
tried to examine the HSC population as early as possible.  As a time course, 
bone marrow cells were collected and stained for HSCs 2, 4, and 7 days after 
tamoxifen injection.  There were changes in sca1 and ckit staining profiles 2 and 
4 days after tamoxifen injection, presumably from tamoxifen injury and recovery 
(Figure 5.1, refer to Figure 2.5 for normal staining profile of HSCs).  This effect 
was largely gone by 7 days.  Therefore, HSCs were sorted from Dot1lF/F and 
Dot1l+/+ mice one week after tamoxifen injection.   
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For the experiment, each genotype had three individuals and all animals 
were between 6-10 weeks of age.  Given that tamoxifen has hormonal effects, 
only males were used to exclude differences that might arise from gender.  
Hence, using female individuals or pooling male and females might give slightly 
different results.  Between 1500-3000 HSCs were collected per individual mouse.  
The difference in HSC numbers were not due to genotype differences but 
correlated with flow rate during the cytometry run, with slower flow rates allowing 
higher collection rates and hence more cells.  Cells were collected directly into 
pre-chilled TRIzol reagent and stored at -150oC until RNA extraction, 
amplification, cDNA synthesis, biotin labeling and fragmentation as mentioned in 
the materials and methods.   
HSC samples were hybridized onto Affymetrix Mouse Gene ST 1.0 arrays 
by the Affymetrix Core (University of Michigan).  The results were first analyzed 
by Cluster 3.0 heat mapping software (Stanford University).  234 genes were 
significantly either upregulated or downregulated with loss of Dot1l with P-value 
cut off at 0.05 (Figure 5.2).  Unfortunately, a lot of the highest hits on first pass 
did not seem very closely connected with each other (Table 5.1).  Therefore, 
Gene Set Enrichment Analysis (GSEA, Broad Institute) was performed.  With 
conventional P-value < 0.05, no enriched pathway was identified.  Hence, a less 
stringent cut off of P=0.2 was used.  The enriched pathways included EZH2 
targets, , myeloid proliferation and renewal, and granulocyte/monocyte 
differentiation (Figures 5.3, 5.4, 5.5).  The red box indicates genes that changed 
expression with P-value < 0.05.  EZH2 is a H3K27 methyltransferase that is a 
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member of the polycomb group protein complex and has been implicated in 
many different cancers (Xiao, 2011).  Upregulation of EZH2 targets made sense 
in that Dot1l and H3K79 methylation are generally associated with gene 
activation while EZH2 and polycomb proteins are associated with gene 
repression.  Also, given the profound disappearance of HSCs, accelerated 
differentiation might be occurring with Dot1l excision.   Based on the P-values of 
pathway components, myeloid proliferation and renewal pathway was the highest 
hit.  These data were partially corroborated by a preliminary cell cycle analysis on 
lineage positive and lineage negative cell populations (Figure 5.6).  
Unfractionated bone marrow was used as lineage positive cells, while lineage 
negative cells were collected by EasySep Mouse Hematopoietic Progenitor Cell 
Enrichment kit (Stem Cell Technology).   Cells were collected 1 week after 
tamoxifen injection.  While the cell population was not very pure, data suggested 
that unfractionated Dot1lF/F cells have defects in cell cycle similar to MLL-AF9 
transformed cells with Dot1l excision, while lineage negative cells show a 
comparable cell cycle profile between Dot1lF/F and Dot1l+/+ with Dot1l excision.  
Better cell cycle analysis with methods such as BrdU incorporation with cell 
surface antibody is required to make further conclusions.  Additional literature 
search is also necessary to determine the details on how myeloid proliferation 
and renewal pathway genes affect cell cycling.   Based on these preliminary data, 
Dot1l excision might lead to induction of closed chromatin structure, accelerated 
differentiation and then cycling block of differentiated cells leading to failure of 




Figure 5.1.  Time course of HSC staining profile after tamoxifen injection.   
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Figure 5.2.  Heat map of 
altered gene expression 
with Dot1l excision in 
HSCs.  P-value < 0.05 
genes were selected.  234 
genes were significantly 
changed.   
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Chd7 chromodomain helicase DNA binding protein 7 
Insl6 insulin-like 6 
Prkcq protein kinase C, theta 
Tacstd2 tumor-associated calcium signal transducer 2 
Ube2h ubiquitin-conjugating enzyme E2H 
Slamf1 signaling lymphocytic activation molecule family member 1 
Fmo5 flavin containing monooxygenase 5 
Zfp273 zinc finger protein 273 
Ccdc69 coiled-coil domain containing 69 
Ankmy2 ankyrin repeat and MYND domain containing 2 
Nupr1 nuclear protein 1 
Polr3gl polymerase (RNA) III (DNA directed) polypeptide G like 
Rmi1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) 
Cnot8 CCR4-NOT transcription complex, subunit 8 
Prim2 DNA primase, p58 subunit 
Trip10 thyroid hormone receptor interactor 10 
Arfgef2 
ADP-ribosylation factor guanine nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 
Trim13 tripartite motif-containing 13 
Nkg7 natural killer cell group 7 sequence 
Ebi3 Epstein-Barr virus induced gene 3 





















































Figure 5.6. Propidium iodide cell cycle analysis of bone marrow cell population.  
UF: unfractionated bone marrow cells.  Lin-: lineage-negative cells remaining 













Other Experiments and Preliminary Results: Histone Cross-Talk 
 
 H2B ubiquitination has been shown to be required for H3K79 methylation 
and H3K4 methylation.  In yeast and in human cell lines, loss of Rad6 (E2 
ubiquitin ligase), Bre1 (E3 ubiquitin ligase for Rad6), or Paf1 complex 
components (required for Rad6-Bre1 activity) led to loss of H3K4 methylation and 
H3K79 methylation (Kim and Roeder, 2011; Ng et al., 2002b; Wood et al., 2003).  
On the contrary, loss of yeast Dot1 and H3K79 methylation does not lead to loss 
of H2B ubiquitination (Ng et al., 2002b).  However, studies examining how the 
loss of H3K79 methylation affects H2B ubiquitination and H3K4 methylation in 
mammalian cells are lacking.  With Dot1lF/F cells transformed by MLL-AF9, we 
examined if Dot1l excision leads to the loss of H3K4 methylation and H2B 
ubiquitination.  Because of the close correlation between H3K79 methylation and 
H3K4 methylation in MLL translocation leukemia (Krivtsov et al., 2008; Milne et 
al., 2005) and the requirement of wild type Mll in MLL-AF9 transformation (Thiel 
et al., 2010), we examined the recruitment of wild type Mll to target gene loci as 
well.  Since our HSC gene expression analysis indicated an increase of EZH2 
targets with Dot1l excision, we also examined the changes of H3K27 methylation 
status.     
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Materials and Methods 
 
Chromatin Immunoprecipitation (ChIP) 
 ChIP samples were prepared from Dot1lF/F cells transformed with MLL-
AF9 and treated with either EtOH or 4-OHT.  Four days after treatment, cells 
were harvested and cross-linked with 1% paraformaldehyde in growth media 
without cytokines for 15 minutes at room temperature.  Cross-linked samples 
were lysed with lysis buffer (1% SDS, 10mM EDTA and 50mM Tris, pH 8.1) for 
15 minutes on ice.  1ml of lysis buffer was used for 10 million cells.  Lysed 
samples were divided into 250µl per microcentrifuge tube and sonicated for 15 
minutes (Bioruptor, Diagenode) on ice and spun down at maximum speed for 15 
minutes at 4oC.  Supernatant of samples were then pooled and diluted 1:10 with 
dilution buffer (0.01% SDS, 1.1% Triton X- 100, 1.2mM EDTA, 16.7mM Tris-HCl, 
pH 8.1, 167mM NaCl).  1% of samples were set aside as input.  Diluted samples 
were divided and antibodies were added for incubation overnight on a rotor.  
Complete mini EDTA-free protease inhibitor cocktail tablet (Roche), 100 M 
PMSF in isopropanol, and 1:1000 aprotinin (Sigma A6279) was added to lysis 
buffer and elution buffer to prevent protein degradation. The next day, Dynabead 
Protein G (Invitrogen, 100-04D) was washed three times with 5% BSA in 1x PBS 
and 30 l was added per sample for immunoprecipitation.  Dynabeads and 
samples were incubated for 1 hour at 4oC on rotor.  Dynabead-bound complex 
was separated with magnet and supernatant discarded.  Samples were then 
washed with low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
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Tris-HCl, pH 8.1, 150mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl), LiCl buffer (0.25M LiCl, 1% 
IGEPAL CA630, 1% deoxycholic acid (sodium salt), 1mM EDTA, 10mM Tris, pH 
8.1), and TE buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA).  The washed samples 
were eluted with 200µl of elution buffer (1%SDS, 0.1M NaHCO3) at 42
oC for 30 
minutes.  Dynabeads were removed from the eluate by magnet and 8µl of 5M 
NaCl were added per sample.  The samples were incubated overnight at 65 oC 
for reverse cross-linking.  DNA was recovered from reverse cross-linked samples 
using QIAquick PCR purification kit (Qiagen 28106).      
 
Antibodies for ChIP 
 Following antibodies were used for ChIP: H3 (Abcam, ab1791), 
H3K79me2 (Abcam, 3594), normal rabbit/mouse IgG (Santa Cruz sc 2027/sc-
2025), H3K4me3 (Millipore 04-745), H3K27me3 (Millipore 17-622), H2BUb 
(Millipore 05-1312), Mll-C (courtesy of Dr. Yali Dou, University of Michigan).   
 
 
Primers for ChIP 













































































































































Table 6.1.  ChIP-qPCR primers. 
 
Data analysis for ChIP 
 ChIP samples were analyzed by qPCR with primers as indicated above.  
Fam-tamra probes were used with Taqman Mastermix (Applied Biosystems).  Ct 
values of qPCR were normalized to input value as internal control and then 
divided with histone 3 (H3) ChIP value, which served as control for the amount of 
nucleosome present on the locus.   
 
HA immunoprecipitation (IP) 
 293 cells were transfected with gene of interest with Fugene 6 (Roche).  
Cells were harvested 2 days later and lysed with BC300 lysis buffer (20mM Tris, 
pH 7.5, 10% glycerol, 300mM KCl, 1mM EDTA, 10mM beta-mercaptoethanol, 
200 M PMSF, 0,1% NP-40) for 30 minutes on ice.  Samples were sonicated 
with a Branson sonicator for 1 minute and spun at maximum speed to remove 
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debris, and then incubated with anti-HA Affinity Matrix from rat IgG (Roche 
11815016001) overnight.  The next day, complexes were washed three times 
with BC300 and proteins were eluted from the matrix by adding Tris-Glycine SDS 
Sample Buffer and heat denaturing for 5 minutes at 95oC.  5% beta-





Loss of H3K79 methylation leads to decrease of H3K4 methylation, Mll-C, 
and H2B ubiquitination, and increase of H3K27 methylation at Hoxa9 and 
Meis1 loci 
 As in all previous experiments with the MLL-AF9 transformed cell line, 
cells were treated with 4-OHT for three days and then cultured for four more days 
in regular growth medium before cross-linking.  Western blot of whole cell lysates 
with histone modification antibodies used for ChIP was performed to examine 
changes in global levels (Figure 6.1).  As expected, H3K79me2 was dramatically 
lost with Dot1l excision.   There might be a slight decrease in H3K4me3 in MLL-
AF9 transformed cells, but H3K27me3 and H2B ubiquitination (H2Bub) remained 
mostly unchanged.  Unchanged H3K27 and H3K4 methylation levels were also 
reported previously (Feng et al., 2010). 
With the excision of Dot1l, H3K79 methylation was totally lost from Hoxa9 
and Meis1 loci as expected (Figure 6.2).  As in previous studies, a strong 
 79 
correlation between H3K79 methylation and H3K4 methylation was observed 
(Krivtsov et al., 2008; Milne et al., 2005), and H3K4 methylation also dramatically 
decreased with some remaining methylation around transcriptional start site 
(Figure 6.3).   We next examined if this loss of H3K4 methylation is due to loss of 
Mll recruitment or due to loss of enzymatic activity even with normal Mll 
recruitment.   In order to differentiate between wild type Mll and MLL-AF9, 
antibody raised against the C-terminus of Mll (Mll-C) was used for ChIP.  ChIP 
with Mll-C showed that recruitment of Mll to the loci was compromised as well 
(Figure 6.4).  This result is notable because global levels of H3K4me3 were 
comparatively less changed (Figure 6.1) or reported unchanged (Feng et al., 
2010).  Western blot of Mll-C may be useful for examining if Dot1l regulates Mll 
expression directly.  Given that there are multiple H3K4 methyltransferases in 
mammals (Shilatifard, 2008), Dot1l loss seemed to specifically affect H3K4 
methylation on Mll target gene loci.  
In contrast to H3K4 methylation, H3K27 methylation increased with Dot1l 
excision (Figure 6.5).  This result corroborates GSEA HSC microarray data 
indicating upregulation of EZH2 targets with the loss of Dot1l.  Similarly to 
H3K4me3 ChIP, these data are notable because there was no change in global 
H3K27 methylation according to western blot (Figure 6.1) and reported data 
(Feng et al., 2010). 
We next examined H2Bub status with Dot1l excision.  As mentioned 
above, H2Bub is required for normal H3K4 and H3K79 methylation in yeast and 
in mammals (Kim et al., 2009; Ng et al., 2002b; Wood et al., 2003).  We wanted 
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to examine if reverse is also true with our Dot1l knockout model.  H2Bub ChIP 
data showed that with loss of Dot1l, H2Bub also decreased (Figure 6.6).  This 
result may be due to several reasons.  With loss of Dot1l, expression of H2B 
ubiquitination machinery may be decreased and hence decrease H2Bub in 
general.  However, this is not likely since global H2B ubiquitination levels did not 
change with Dot1l excision (Figure 6.1).  Preliminary immunoprecipitation 
experiments also showed that Dot1l and Paf1 complex member Ctr9 (Rozenblatt-
Rosen et al., 2005; Zhu et al., 2005) did not interact (Figure 6.7).  It will be 
interesting to examine the expression and recruitment of Rad6, Bre1, and Paf1 
complex components to the Hoxa9 and Meis1 loci as well.   This result also 
raises interesting questions on histone cross-talk, because on specific loci 
H3K79 methylation seemed to affect other histone modification, but presumably 
not for all loci based on global western blot data.  
                   
Figure 6.1.  Western blot of whole cell lysate after Dot1l excision.  In general, 
global levels of examined histone modifications other than H3K79 methylation 
remained stable.   
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Figure 6.2. H3K79me2 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.  




Figure 6.3. H3K4me3 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.  H3K4 




Figure 6.4. Mll-C ChIP of Hoxa9 and Meis1 loci after Dot1l excision.  Recruitment 
of wild type Mll was compromised.   
 
 
Figure 6.5. H3K27me3 ChIP of Hoxa9 and Meis1 loci after Dot1l excision.  





Figure 6.6. H2Bub ChIP of Hoxa9 and Meis1 loci after Dot1l excision.  H2B 
ubiquitination was reduced.   
 
    
                             
 
Figure 6.7.  HA tagged Dot1l was overexpressed in 293 cells and 
immunoprecipitated (IP) with HA antibody.  Western blot (WB) with HA show that 
HA-Dot1l was significantly enriched in IP sample but Paf complex component 




Other Experiments and Preliminary Results: Dot1l-AF9/ENL interaction 
   
 In collaboration with Dr. Zaneta Nikolovska-Coleska’s lab we examined 
the effects of Dot1l-AF9/ENL interaction in MLL-AF9 transformation.  AF9 and 
ENL are both common MLL translocation partners, and the two proteins show 
high homology especially in the C-terminus which is involved in MLL 
translocation (Figure 7.1).  Together, they constitute ~25% of acute lymphoid 
leukemia (ALL) and ~35% of acute myeloid leukemia (AML) with MLL 
translocations (Meyer et al., 2009).  It was interesting as mentioned in Chapter III 
that MLL-AF9 transformed cells were specifically affected by Dot1l loss.  Hence, 
Chenxi Shen from Dr. Nikolovska-Coleska’s lab studied the interaction domain of 












She was able to narrow down the interaction region to 10 amino acids, 
showing that in vitro the 10 amino acid peptide can disrupt interaction between 
Dot1l and AF9/ENL.  From these data, we examined the effect of these 10 amino 
acids on MLL-AF9 transformation.  A full length HA-tagged Dot1l construct was 
made with the 10 amino acid deletion (10aa ).  Rescue of transformation by this 
construct was compared to those of full length wild type Dot1l and enzymatically 
inactive Dot1l (RCR) constructs (Figures 3.18 and 3.19). 
 
 
Materials and Methods 
 
All methods for this section were as indicated in Chapter III. 150,000 MLL-





10aa construct retains H3K79 methylation ability but loses transformation 
ability 
 MLL-AF9 transformed cells from Chapter III were used as starting point for 
experiments in Chapter VII.  The MLL-AF9 transformed cell line was transduced  
twice with neomycin (Neo) vector control, wild type Dot1l, enzymatically inactive 
Dot1l (RCR), and AF9 interaction defective Dot1l (10aa ).  2-3 days after the 
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last transduction, cells were plated on methocult media with EtOH or 4-OHT.  
Once the plates became confluent 5-7 days later, cells were replated onto 
methocult media.  Colony formation were count from the 2nd plating (Figure 7.2) 
 







Figure 7.2.  Schematic of transduction of MLL-AF9 transformed cells. 
 
 
 Cells left over from the 1st plating were used for genomic DNA, RNA, and 
protein extraction.  PCR reaction of genomic DNA showed clear excision of 
endogenous Dot1l loci (Figure 7.3).    
             
Figure 7.3.  Genotyping of transduced bone marrow cells after first round.  PCR 
reaction showed high excision efficiency with 4-OHT treatment in all cells.   
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qPCR of HA tag showed that all exogenous Dot1l constructs were 
expressed compared to neomycin vector control (Figure 7.4).            
  
Figure 7.4.  qPCR of HA tag and N-terminus of Dot1l.  All Dot1l constructs 
showed high expression compared to vector alone.   
 
The functionality of the 10aa  construct was examined by western blot.  
Western blot of H3K79me2 showed that H3K79 methylation was restored with 
expression of exogenous wild type Dot1l and 10aa  constructs, but not with 
RCR construct (Figure 7.5).  Restoration of H3K79 methylation by the 10aa  
construct is in contrast to the HMT domain construct (Figure 7.5 and Figure 3.17).  
This result suggested that for in vivo H3K79 methylation the C-terminal region of 
Dot1l is also required, unlike for in vitro methylation assays (Feng et al., 2002; 
Min et al., 2003).  Given the restoration of H3K79 methylation, the transformation 
ability of the 10aa  construct was of particular interest.  Unlike the wild type 
Dot1l construct, expression of the AF9/ENL interaction domain lacking 10aa  
construct failed to rescue colony formation after endogenous Dot1l excision 
(Figures 7.6 & 7.7).   
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Figure 7.5.  Western blot of H3K79Me2 after first round.  Western blot showed 
restoration of H3K79Me2 with the introduction of exogenous wild type Dot1l and 
10aa  but not with RCR.  Histone 3 blot was used as loading control. 
 
            
Figure 7.6.  Quantification of colony formation by MLL-AF9 transformed cells with 
endogenous Dot1l excision and exogenous Dot1l constructs (wild type-Dot1l, 
methyltransferase inactive-RCR and AF9/ENL interaction domain lacking-





Figure 7.7. Whole plate image of colony formation by MLL-AF9 transformed cells 
after endogenous Dot1l excision and exogenous Dot1l expression.  INT staining 
at 2nd round.    
 
In fact, despite the restoration of H3K79 methylation, colony formation by 
the 10aa  construct mimicked that of neomycin vector control and RCR 
constructs.  This result is significant because it suggested that interrupting this 
key interaction with a peptide or small molecule could also disrupt colony 
formation by MLL-AF9 transformed cells, which in the clinic could lead to 
remission.  Due to high homology between AF9 and ENL (Figure 7.1) and 
identical interaction residues on Dot1l, similar results are expected with MLL-ENL.  
Further studies will be necessary to determine if other MLL translocation proteins 
will be affected by targeting these interaction residues on Dot1l.  It will also be 
interesting to perform a detailed analysis of interaction domains between Dot1l 







This thesis focuses on the biological role of Dot1l in mammalian 
hematopoietic system.  With our conditional Dot1l knockout mouse model, we 
showed that Dot1l is required for maintaining postnatal hematopoiesis as well as 
leukemogenesis by MLL translocation.  Dot1l deletion led to the failure of 
hematopoietic homeostasis and to the loss of functional HSCs in a cell-
autonomous manner. Moreover, Dot1l was selectively required for the 
transformation by MLL translocation proteins but not by Hoxa9/Meis1 and E2A-
HLF oncogenes.  Interestingly, both the histone methyltransferase activity of 
Dot1l and the protein interaction by Dot1l were important in transformation by the 
MLL-AF9 oncogene.  In addition, Dot1l loss led to upregulation of polycomb 
target genes and differentiation-related genes in HSCs, and the loss of H3K79 
methylation affected histone modification status on selected gene loci in MLL-
AF9 transformed cells instead of leading to global changes.    
 
Dot1l and normal hematopoiesis 
 Our studies clearly show the requirement of Dot1l in normal postnatal 
hematopoiesis.  Extended Dot1l loss (~8 weeks) led to bone marrow atrophy and 
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pancytopenia that was more extensive compared to other organs (Figures 2.2, 
2.3 and 4.1).  Transplantation experiments showed that Dot1l lacking HSCs 
could not reconstitute bone marrow, and this effect was cell autonomous.  The 
excision of Dot1l in normal hematopoietic microenvironment with competitors 
showed that even relatively short period of Dot1l loss (~2 weeks) led to profound 
disappearance of Dot1l-deficient cells particularly for short-lived myeloid cells 
(Figure 2.13).   
From our data, question arises on how Dot1l excision affects HSCs, 
progenitors and circulating blood cells.  By third week, HSCs and progenitors of 
all blood lineages showed significant decrease in frequency (Figure 2.6).  
However, animals survived and CBC did not drop significantly until ~8 weeks 
after Dot1l excision (Figure 2.3).  This suggested that effects of Dot1l loss are 
likely not due to indiscriminant toxicity to cells.  If loss of Dot1l and H3K79 
methylation led to generalized chromosomal defects, then all nucleated cells 
would be affected catastrophically.  On the other hand, it is possible that there 
were a few cells that escaped excision and that these cells were responsible for 
the reduced toxicity observed in these mice.  The repopulation of peripheral 
blood by cells that escaped excision was observed by PCR reaction at 4-5 weeks 
after initial tamoxifen injection, and for this reason tamoxifen was injected every 4 
weeks to ensure Dot1l excision.  Peripheral blood was used for excision check 
before and after each tamoxifen injection (3-5 days before and after the injection 
date), and with the every 4 week injection schedule there was no detectable 
unexcised allele from PCR.  However, the presence of PCR-undetectable cells 
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that escaped excision cannot be completely ruled out.  If this were the case, then 
it will suggest that in fact Dot1l loss is catastrophically toxic and that there is a 
huge selection against Dot1l loss.  One way to possibly test this hypothesis is to 
perform transplantation experiment without the competitor cells.  In the absence 
of competitor cells, the few cells that escaped excision may be able to repopulate 
the recipient bone marrow.  Another way to examine this hypothesis is to analyze 
chromosomal structure of cells after Dot1l excision with time course metaphase 
spread.  If there are chromosomal defects shortly after excision in most of the 
cells with a few exceptions (presumable those that escaped excision), then it will 
suggest that in fact Dot1l loss is extremely toxic to cells.  It is also notable that 
enzymatic demethylation of H3K79 residue has not been reported.  Hence, 
H3K79 methylation may persist longer than other histone modifications that can 
be enzymatically removed especially for slow-cycling cells.  This may contribute 
to delayed toxicity.  For example, demethylase LSD1 has been shown to remove 
H3K4 methylation mark (Shi et al., 2004).    Eight week survival by Dot1l lacking 
mice is in contrast to Mll lacking mice that died by three weeks after excision 
(Jude et al., 2007).   
 Gene expression data from HSC microarray suggested a possible 
mechanism of Dot1l action in hematopoiesis.  GSEA data indicated upregulation 
of EZH2 targets (Figure 5.3), with many of them associated with cell cycle, such 
as Prc1 (Jiang et al., 1998), Mcm3 (Madine et al., 1995), and Ccnb2 (Gong and 
Ferrell, 2010).  GSEA data also indicated upregulation of myeloid proliferation 
and self-renewal genes (Figure 5.4).  Combined with possible increase in HSC 
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cell cycle, this data might imply acceleration of differentiation into myeloid lineage, 
with depletion of HSCs and lymphocyte, megakaryocyte, and erythrocyte lineage 
progenitors.  Loss of renewable HSCs will eventually lead to depletion of myeloid 
lineage progenitors as well.  Frequency of cell population roughly correlates with 
this hypothesis, with HSC loss being most severe, then CLP (furthest from 
myeloid pathway), then MkP similar to EryP (separated from myeloid pathway 
later than CLP), and GMP being least depleted (Figure 2.7).  In addition, GSEA 
data suggested that granulocyte and monocyte differentiation downstream of the 
initial myeloid commitment may be affected by Dot1l loss (Figure 5.5).  While it is 
unclear if and how these genes affect cell cycle, preliminary cell cycle analysis 
implied that there may be cell cycle block in more differentiated cells (Figure 5.6).  
From these data, it can be hypothesized that Dot1l loss leads to increased 
cycling and accelerated myeloid differentiation of HSCs and then cell cycle block 
near the end of differentiation pathway, eventually leading to hematopoietic 
failure.   
Several experiments can be proposed to test this hypothesis.  Firstly, 
HSCs and progenitor population frequency can be examined after shorter period 
of Dot1l excision.  Although use of tamoxifen for Dot1l excision led to staining 
profile changes in bone marrow and precluded analysis prior to one week (Figure 
5.1), we can perform time course experiment for population analysis between 
one and three weeks.  If the hypothesis of accelerated differentiation into myeloid 
pathway is true, then there might be a time period where frequencies of HSCs 
and other lineage progenitors are decreasing but there is no change or increase 
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in GMPs.  Similarly, cell cycle analysis of individual cell population can be 
performed in a time course.  There are two approaches to cell cycle analysis.  
One is first staining for cell surface markers, sorting and collecting cell 
populations, fixing the cells, and using DNA intercalating agents such as 
propidium iodide or DAPI for examining DNA content.  Use of DAPI is preferable 
to propidium iodide because it interferes less with emissions of other 
fluorophores.  This approach is limited in analyzing low frequency population 
because of the inherent loss of cells while fixing and staining small number of 
cells, and at least 5000-10000 events are necessary during the second flow 
cytometer run to get good DNA content profile (example Figure 3.9).  On the 
other hand, this approach separates efficiency of cell surface marker staining and 
DNA content analysis.  Once the cells are sorted and collected by the surface 
marker profile, the population of cells is set and any incompatibility of surface 
marker antibodies and fixation treatment or intercalating reagent is not very 
important.  Also, this approach does not require any prior treatment of animals or 
cells unlike the second approach.  The second approach is using BrdU and anti-
BrdU antibody.  Animals are injected with BrdU 12 hours prior to analysis, bone 
marrow cells or peripheral blood cells are harvested and stained for cell surface 
markers, and cells are fixed, permeabilized and stained for BrdU-antibody.  BrdU 
staining requires cell surface antibodies to remain bound and fluorophores to be 
intact through fixation and permeabilization processes.  BrdU itself may also be 
toxic to the cells, although the effects are likely to be minimal with only 12 hour 
exposure.  If good surface staining can be obtained, BrdU staining can be useful 
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in examining all cell population.   With detailed cell cycle analysis with time 
course, effects of Dot1l excision on HSCs, progenitors and differentiated cells 
can be compared.  If our hypothesis of accelerated HSC myeloid differentiation 
and cell cycle block downstream is true, then there may be initial increase in 
HSC cycling and then decrease in GMP cycling.  Additionally, gene expression 
profiles of populations other than HSCs can be examined and compared to 
understand the effects of Dot1l excision in more differentiated cells.    
Another interesting question is determining the relative importance of HMT 
activity of Dot1l and protein interaction by Dot1l in normal hematopoiesis.  This 
question is derived in part from Chapter VII of the thesis, where deletion of Dot1l-
AF9 interaction residues of Dot1l was as detrimental to MLL-AF9 transformation 
as removing enzymatic activity of Dot1l.  If normal hematopoiesis can be rescued 
by 10aa  construct that retains HMT activity but cannot interact with AF9, then 
there will be a very high therapeutic index targeting Dot1l-AF9 interaction region.  
Several experiments can be designed to test this idea.  Transplantation 
experiments can be done in two ways.  Bone marrow cells can be harvested from 
Dot1lF/F mice and transduced with either vector control or 10aa  construct.  The 
cells can then be treated with 4-OHT in vitro for Dot1l excision and transplanted 
into lethally irradiated recipient mice with varying ratios of competitive cells.  If 
experimental cells can reconstitute recipient bone marrow in the presence of 
competitors, then it is a very strong evidence that Dot1l-AF9 interaction is non-
essential in HSC activity.  Or, the transduced cells can be transplanted first into 
recipients and allowed to reconstitute recipient bone marrow.  Then the recipients 
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will be injected with tamoxifen for Dot1l excision in vivo.  The second method 
assures that experimental cells are not competed out at the initial engraftment 
stage before 10aa  construct expression is stable and also examine if any 
observed phenotype is cell autonomous.  More sophisticated method of 
examining the activity of 10aa  construct in hematopoiesis is to generate 
transgenic mice from the conditional Dot1l knockout line.  One approach is 
starting with our homozygous Dot1F/F mice and expressing 10aa  construct.   A 
vector with ubiquitously expressed promoter such as ROSA26 with 
transcriptional termination sequences flanked with loxp sequences can be used 
(Soriano, 1999).  10aa  construct can be cloned into this vector 3’ to the flanked 
transcriptional termination sequences.  The embryos will be microinjected with 
this vector for random integration into genome.  This approach has the 
disadvantage of exogenous promoter driven expression and random integration 
while having the advantage of expressing Dot1l protein with just the minimal 10 
amino acid deletion required for Dot1l-AF9 interaction.  Alternatively, exon 20 
that contains the Dot1l-AF9 interaction residues can be deleted out similarly to 
exon 2 deletion conditional knockout mice generated in this thesis (Figure 2.1).  
However, exon 20 is 484 base pairs long, so more than the 10 amino acids 
required for the interaction will be lost.  However, this approach has the 
advantage of being endogenous promoter driven expression and no random 
integration.   In both cases, Cre induction will lead to expression of Dot1l that 
cannot interact with AF9.    If hematopoietic homeostasis can be maintained in 
these animals after endogenous Dot1l excision, then it will strongly suggest that 
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targeting Dot1l-AF9 interaction will yield high therapeutic index and also suggest 
that Dot1l-AF9 interaction is dispensable for hematopoietic homeostasis, 
indicating that Dot1l acts through other proteins to affect hematopoiesis.  This 
mice model may also be more physiologically similar to patients who may be 
taking a drug targeting Dot1l-AF9 interaction.  In addition to hematopoiesis, 
Dot1l-AF9 interaction has been shown to be important in both brain development 
(Büttner et al., 2010) and regulation of sodium channels in kidneys (Zhang et al., 
2006).  As more biological roles of Dot1l-AF9 interactions are reported, 
generation of these mice may prove to be useful.  Similar studies can also be 
performed with a good inhibitor targeting Dot1l-AF9 interaction region. 
 
The role of Dot1l in HSCs versus LICs 
One of the most interesting findings of this thesis is the selective nature of 
Dot1l function depending on cell type.  Remarkably, normal HSCs and MLL-AF9 
LICs required proper Dot1l expression while Hoxa9/Meis1 and E2A-HLF LICs did 
not.  It is notable that cells with MLL-AF9 oncogene showed phenotype similar to 
normal HSCs instead of acting similarly to cells with other leukemic oncogenes.  
There are some evidences indicating that MLL translocation ALL and AML may 
be a separate category apart from other ALL and AML.  As the name Mixed 
Lineage Leukemia suggests, MLL translocation can lead to either ALL or AML.  
Gene expression profiling study shows that ALL and AML with MLL translocation 
clusters together instead of clustering with other ALL and AML cases (Zangrando 
et al., 2009).  Hence, despite the phenotypic similarity to ALL and AML with other 
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oncogenes, MLL translocation leukemia seems to have separate gene regulation, 
which may be similar to HSCs.   
Dependence on major MLL translocation target genes may be a possible 
explanation for the phenotypic distinction between cell types with Dot1l excision.  
Both normal HSCs and MLL translocation leukemia are dependent on Hoxa9 and 
Meis1.  Previous studies on Hoxa9 and Meis1 knockout mice show that both 
proteins, especially Meis1, are critical for normal HSCs (Hisa et al., 2004; 
Lawrence et al., 1997).  Similarly, it is well documented that Hoxa9 and Meis1 
are important in the maintenance of MLL translocation leukemia (Ayton and 
Cleary, 2003; Zeisig et al., 2004).  Dot1l binds directly to the Hoxa9 and Meis1 
loci and H3K79 methylation levels are closely correlated with gene expression 
(Monroe et al., 2010), indicating that Dot1l is a direct regulator of these genes.  In 
contrast, Hoxa9/Meis1 transformed cells have high expression of both proteins 
through exogenous promoters, and E2A-HLF cells do not upregulate Hoxa9 and 
Meis1 expression.  The varying dependence on Hoxa9 and Meis1 in different cell 
types might explain the different response to Dot1l deletion.  It will be interesting 
to compare gene expression changes with Dot1l loss among normal HSCs and 
cells transformed with MLL-AF9, Hoxa9/Meis1, and E2A-HLF.   
 
Dot1l as a therapeutic target 
The requirement of Dot1l by MLL translocation protein makes Dot1l an 
attractive target for therapy, particularly since Dot1l-deficient mice did not show 
overt toxicity for the first 7-8 weeks of Dot1l excision.  From our data, 
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hematopoietic toxicity may complicate the long-term use of DOT1L inhibitors.  
However, many myelotoxic drugs are successfully used clinically.  A pulse of 
DOT1L inhibition may not be unmanageably toxic, especially with supporting 
therapies such as transfusion.  In addition, it is possible that a partial reduction in 
Dot1l activity may show greater toxicity for leukemia cells compared to normal 
HSCs based on the concept of oncogene addiction (Sharma and Settleman, 
2010).  Furthermore, the use of DOT1L inhibition may be broadened by targeting 
other leukemias with upregulated HOXA9 and MEIS1 expression such as those 
with CDX2/CDX4 and NPM1 mutations (Renneville et al., 2008).  DOT1L may 
downregulate HOXA9 and MEIS1 expression in these other leukemias and have 
similar anti-leukemia effect.   
It is notable that in addition to targeting HMT activity of Dot1l, targeting 
Dot1l interaction with an important co-activator for a particular cell type can be 
equally biologically effective.  Inactivating HMT domain or deleting protein 
interaction domain of Dot1l had similar effects in suppressing colony formation on 
methocult (Figures 7.6 and 7.7), suggesting that either function can be targeted 
for therapeutic effects.  Given that the Dot1l construct lacking AF9/ENL 
interaction residues retained H3K79 methylation (Figure 7.5), targeting the region 
might have lower toxicity compared to targeting the HMT domain for treating 
MLL-AF9 and MLL-ENL leukemias.  In addition to MLL translocation partners, 
Dot1l has been shown to interact with Wnt pathway components (Mohan et al., 
2010).  Different interaction partners of Dot1l probably bind slightly different 
residues of Dot1l.  By identifying specific residues of Dot1l responsible for 
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interacting with essential co-activator and targeting them, it may be possible to 
achieve high therapeutic index and broaden the use of Dot1l targeting drugs.      
 
Gene regulation by Dot1l, H3K79 methylation, and co-activators 
ChIP results in MLL-AF9 transformed cells revealed interesting histone 
cross-talk in mammalian cells.  Previous studies show that H2B ubiquitination is 
required for H3K4 and H3K79 methylation (Kim et al., 2009; Ng et al., 2003; 
Wood et al., 2003), and H3K79 methylation closely correlates with H3K4 
methylation in MLL translocation leukemia cells (Krivtsov et al., 2008; Lin et al., 
2009).  Our preliminary ChIP data on Hoxa9 and Meis1 loci clearly showed that 
both H3K4 methylation and H2B ubiquitination decreased with H3K79 
methylation loss.  These modification changes were likely loci specific because 
total modification levels did not change with Dot1l excision (Figure 6.1).  It will be 
interesting to perform ChIP-seq of histone modifications before and after Dot1l 
excision and study which modifications vary together at which loci and correlate 
the data with gene expression analysis.   
As mentioned above, H3K79 methylation by Dot1l and Dot1l-AF9 
interaction were required for transformation by the MLL-AF9 oncogene.  MLL-
AF9 transformed cells with HA-tagged Dot1l, RCR, and 10aa  constructs 
provide a unique system to study gene regulation by Dot1l and H3K79 
methylation.  Recruitment of the Dot1l and H3K79 methylation status in cells with 
HA-tagged Dot1l, RCR, and 10aa  constructs through ChIP-seq in conjunction 
with gene expression profile can be performed.  Comparing cells with wild type 
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Dot1l and those with RCR will shed light on genes that are specifically regulated 
by H3K79 methylation.  In addition, comparing cells with wild type Dot1l and 
those with 10aa  will show more subtle regulation of loci that require Dot1l-
AF9/ENL interaction.   
 
Dot1l and other organ systems 
The biological role of Dot1l is likely to be beyond hematopoiesis and 
leukemia.  A study shows that DOT1L is involved in regulation of tumor 
suppressor gene expression in human colon carcinoma cell lines (Jacinto et al., 
2009).  Dot1l has also been shown to be important in gut development 
(Mahmoudi et al., 2010) and kidney function (Zhang et al., 2006).   Also, a recent 
study shows that Dot1l loss in cardiac muscle leads to defects in heart 
development, arrhythmia, and death (Nguyen et al., 2011).  Our observations 
also showed atrophy of seminiferous tubules and decreased but not abolished 
sperm production.  It will be interesting to study if these sperm are actually 
functional.  Furthermore, Dot1l and AF9 have been shown to be important for 
proper brain development (Büttner et al., 2010).  In the case of our conditional 
Dot1l knockout mice, tissue immunohistochemistry after Dot1l excision showed 
that the brain tissue retained H3K79 methylation (Figure 4.1).  Because Dot1l is 
the only H3K79 methyltransferase and current studies not support secondary 
methyltransferases for the H3K79 residue, it was initially suspected that the 
blood-brain barrier might have prevented uptake of tamoxifen into the brain.  
However, presentation by Dr. Andrew Lieberman’s lab (University of Michigan) 
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showed that complete excision of a target gene was observed in the brain with 
identical ROSA-CreER system.  Hence, further examination will be necessary to 
explain this discrepancy.   
 
Concluding remarks 
In summary, our studies showed that Dot1l is an important histone 
modifier with interesting biological functions.  We established the requirement of 
Dot1l in normal postnatal hematopoiesis and the essential role of Dot1l in MLL 
translocation mediated leukemogenesis.  Tissue immunohistochemistry, gene 
expression analysis, ChIP-qPCR, and mutant Dot1l construct rescue 
experiments further shed light on the subtle gene regulation by Dot1l and opened 
up questions for future studies.  We hope that these findings broaden the 
understanding of the regulation of HSCs and the pathogenesis of MLL 













Ayton, P.M., and Cleary, M.L. (2003). Transformation of myeloid progenitors by 
MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17, 2298-2307. 
Barry, E., Krueger, W., Jakuba, C., Veilleux, E., Ambrosi, D., Nelson, C., and 
Rasmussen, T. (2009). ES cell cycle progression and differentiation require the 
action of the histone methyltransferase Dot1L. Stem Cells 27, 1538-1547. 
Barry, E.R., Corry, G.N., and Rasmussen, T.P. (2010). Targeting DOT1L action 
and interactions in leukemia: the role of DOT1L in transformation and 
development. Expert Opin Ther Targets 14, 405-418. 
Benedikt, A., Baltruschat, S., Scholz, B., Bursen, A., Arrey, T.N., Meyer, B., 
Varagnolo, L., Müller, A.M., Karas, M., Dingermann, T., et al. (2011). The 
leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and 
altered epigenetic signatures. Leukemia 25, 135-144. 
Bitoun, E., Oliver, P., and Davies, K. (2007). The mixed-lineage leukemia fusion 
partner AF4 stimulates RNA polymerase II transcriptional elongation and 
mediates coordinated chromatin remodeling. Hum Mol Genet 16, 92-106. 
Bursen, A., Schwabe, K., Rüster, B., Henschler, R., Ruthardt, M., Dingermann, T., 
and Marschalek, R. (2010). The AF4.MLL fusion protein is capable of inducing 
ALL in mice without requirement of MLL.AF4. Blood 115, 3570-3579. 
Büttner, N., Johnsen, S.A., Kügler, S., and Vogel, T. (2010). Af9/Mllt3 interferes 
with Tbr1 expression through epigenetic modification of histone H3K79 during 
development of the cerebral cortex. Proc Natl Acad Sci U S A 107, 7042-7047. 
Chandrasekharan, M.B., Huang, F., and Sun, Z.W. (2010). Histone H2B 
ubiquitination and beyond: Regulation of nucleosome stability, chromatin 
dynamics and the trans-histone H3 methylation. Epigenetics 5. 
Chang, M.J., Wu, H., Achille, N.J., Reisenauer, M.R., Chou, C.W., Zeleznik-Le, 
N.J., Hemenway, C.S., and Zhang, W. (2010). Histone H3 lysine 79 
methyltransferase Dot1 is required for immortalization by MLL oncogenes. 
Cancer Res 70, 10234-10242. 
Crissman, H.A., Oka, M.S., and Steinkamp, J.A. (1976). Rapid staining methods 
for analysis of deoxyribonucleic acid and protein in mammalian cells. J 
Histochem Cytochem 24, 64-71. 
Dou, Y., and Hess, J.L. (2008). Mechanisms of transcriptional regulation by MLL 
and its disruption in acute leukemia. Int J Hematol 87, 10-18. 
Dou, Y., Milne, T.A., Ruthenburg, A.J., Lee, S., Lee, J.W., Verdine, G.L., Allis, 
C.D., and Roeder, R.G. (2006). Regulation of MLL1 H3K4 methyltransferase 
activity by its core components. Nat Struct Mol Biol 13, 713-719. 
Dou, Y., Milne, T.A., Tackett, A.J., Smith, E.R., Fukuda, A., Wysocka, J., Allis, 
C.D., Chait, B.T., Hess, J.L., and Roeder, R.G. (2005). Physical association and  
 
 104 
coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 
acetyltransferase MOF. Cell 121, 873-885. 
Feng, Q., Wang, H., Ng, H., Erdjument-Bromage, H., Tempst, P., Struhl, K., and 
Zhang, Y. (2002). Methylation of H3-lysine 79 is mediated by a new family of 
HMTases without a SET domain. Curr Biol 12, 1052-1058. 
Feng, Y., Yang, Y., Ortega, M.M., Copeland, J.N., Zhang, M., Jacob, J.B., Fields, 
T.A., Vivian, J.L., and Fields, P.E. (2010). Early mammalian erythropoiesis 
requires the Dot1L methyltransferase. Blood 116, 4483-4491. 
Gong, D., and Ferrell, J.E. (2010). The roles of cyclin A2, B1, and B2 in early and 
late mitotic events. Mol Biol Cell 21, 3149-3161. 
Grez, M., Akgün, E., Hilberg, F., and Ostertag, W. (1990). Embryonic stem cell 
virus, a recombinant murine retrovirus with expression in embryonic stem cells. 
Proc Natl Acad Sci U S A 87, 9202-9206. 
Hanson, R.D., Hess, J.L., Yu, B.D., Ernst, P., van Lohuizen, M., Berns, A., van 
der Lugt, N.M., Shashikant, C.S., Ruddle, F.H., Seto, M., et al. (1999). 
Mammalian Trithorax and polycomb-group homologues are antagonistic 
regulators of homeotic development. Proc Natl Acad Sci U S A 96, 14372-14377. 
Hawley, R.G., Lieu, F.H., Fong, A.Z., and Hawley, T.S. (1994). Versatile retroviral 
vectors for potential use in gene therapy. Gene Ther 1, 136-138. 
Hermiston, M.L., Xu, Z., and Weiss, A. (2003). CD45: a critical regulator of 
signaling thresholds in immune cells. Annu Rev Immunol 21, 107-137. 
Hisa, T., Spence, S.E., Rachel, R.A., Fujita, M., Nakamura, T., Ward, J.M., 
Devor-Henneman, D.E., Saiki, Y., Kutsuna, H., Tessarollo, L., et al. (2004). 
Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J 23, 
450-459. 
Huret, J.L., Dessen, P., and Bernheim, A. (2001). An atlas of chromosomes in 
hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15, 
987–989. 
Jacinto, F.V., Ballestar, E., and Esteller, M. (2009). Impaired recruitment of the 
histone methyltransferase DOT1L contributes to the incomplete reactivation of 
tumor suppressor genes upon DNA demethylation. Oncogene 28, 4212-4224. 
Jiang, W., Jimenez, G., Wells, N.J., Hope, T.J., Wahl, G.M., Hunter, T., and 
Fukunaga, R. (1998). PRC1: a human mitotic spindle-associated CDK substrate 
protein required for cytokinesis. Mol Cell 2, 877-885. 
Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G., Kadam, S., 
Zhai, H., Valdez, R., et al. (2008). The histone H3K79 methyltransferase Dot1L is 
essential for mammalian development and heterochromatin structure. PLoS 
Genet 4, e1000190. 
Jude, C., Climer, L., Xu, D., Artinger, E., Fisher, J., and Ernst, P. (2007). Unique 
and independent roles for MLL in adult hematopoietic stem cells and progenitors. 
Cell Stem Cell 1, 324-337. 
Karlić, R., Chung, H., Lasserre, J., Vlahovicek, K., and Vingron, M. (2010). 
Histone modification levels are predictive for gene expression. Proc Natl Acad 
Sci U S A 107, 2926-2931. 
 105 
Kiel, M., Yilmaz, O., Iwashita, T., Terhorst, C., and Morrison, S. (2005). SLAM 
family receptors distinguish hematopoietic stem and progenitor cells and reveal 
endothelial niches for stem cells. Cell 121, 1109-1121. 
Kim, J., Guermah, M., McGinty, R.K., Lee, J.S., Tang, Z., Milne, T.A., Shilatifard, 
A., Muir, T.W., and Roeder, R.G. (2009). RAD6-Mediated transcription-coupled 
H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell 137, 
459-471. 
Kim, J., and Roeder, R.G. (2011). Nucleosomal H2B ubiquitylation with purified 
factors. Methods. 
Komura, K., Itakura, K., Boyse, E.A., and M., J. (1975). Ly-5: a new lymphocyte 
antigen system. Immunogenetics 1, 452-456. 
Kopp, H.G., Avecilla, S.T., Hooper, A.T., and Rafii, S. (2005). The bone marrow 
vascular niche: home of HSC differentiation and mobilization. Physiology 
(Bethesda) 20, 349-356. 
Krivtsov, A., Feng, Z., Lemieux, M., Faber, J., Vempati, S., Sinha, A., Xia, X., 
Jesneck, J., Bracken, A., Silverman, L., et al. (2008). H3K79 methylation profiles 
define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368. 
Krivtsov, A.V., and Armstrong, S.A. (2007). MLL translocations, histone 
modifications and leukaemia stem-cell development. Nat Rev Cancer 11, 823-
833. 
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., and 
Sauvageau, G. (1998). Hoxa9 transforms primary bone marrow cells through 
specific collaboration with Meis1a but not Pbx1b. EMBO J 17, 3714-3725. 
Lavau, C., Szilvassy, S.J., Slany, R., and Cleary, M.L. (1997). Immortalization 
and leukemic transformation of a myelomonocytic precursor by retrovirally 
transduced HRX-ENL. EMBO J 16, 4226-4237. 
Lawrence, H.J., Helgason, C.D., Sauvageau, G., Fong, S., Izon, D.J., Humphries, 
R.K., and Largman, C. (1997). Mice bearing a targeted interruption of the 
homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid 
hematopoiesis. Blood 89, 1922-1930. 
Lee, J., Shukla, A., Schneider, J., Swanson, S., Washburn, M., Florens, L., 
Bhaumik, S., and Shilatifard, A. (2007). Histone crosstalk between H2B 
monoubiquitination and H3 methylation mediated by COMPASS. Cell 131, 1084-
1096. 
Lin, Y., Kakadia, P., Chen, Y., Li, Y., Deshpande, A., Buske, C., Zhang, K., 
Zhang, Y., Xu, G., and Bohlander, S. (2009). Global reduction of the epigenetic 
H3K79 methylation mark and increased chromosomal instability in CALM-AF10-
positive leukemias. Blood 114, 651-658. 
Madine, M.A., Khoo, C.Y., Mills, A.D., and Laskey, R.A. (1995). MCM3 complex 
required for cell cycle regulation of DNA replication in vertebrate cells. Nature 
375, 421-424. 
Mahmoudi, T., Boj, S.F., Hatzis, P., Li, V.S., Taouatas, N., Vries, R.G., 
Teunissen, H., Begthel, H., Korving, J., Mohammed, S., et al. (2010). The 
leukemia-associated Mllt10/Af10-Dot1l are Tcf4/β-catenin coactivators essential 
for intestinal homeostasis. PLoS Biol 8, e1000539. 
 106 
Maillard, I., Chen, Y., Friedman, A., Yang, Y., Tubbs, A., Shestova, O., Pear, W., 
and Hua, X. (2009). Menin regulates the function of hematopoietic stem cells and 
lymphoid progenitors. Blood 113, 1661-1669. 
Martin, M.E., Milne, T.A., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, 
H.W., Slany, R., and Hess, J.L. (2003). Dimerization of MLL fusion proteins 
immortalizes hematopoietic cells. Cancer Cell 4, 197-207. 
Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben 
Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., et al. (2009). 
New insights to the MLL recombinome of acute leukemias. Leukemia 23, 1490-
1499. 
Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis, C.D., and 
Hess, J.L. (2001). MLL targets SET domain methyltransferase activity to Hox 
gene promoters. Mol Cell 10, 1107-1117. 
Milne, T.A., Martin, M.E., Brock, H.W., Slany, R.K., and Hess, J.L. (2005). 
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 
locus, promoting transcription and multiple histone modifications. Cancer Res 65, 
11367-11374. 
Min, J., Feng, Q., Li, Z., Zhang, Y., and Xu, R. (2003). Structure of the catalytic 
domain of human DOT1L, a non-SET domain nucleosomal histone 
methyltransferase. Cell 112, 711-723. 
Mohan, M., Herz, H.M., Takahashi, Y.H., Lin, C., Lai, K.C., Zhang, Y., Washburn, 
M.P., Florens, L., and Shilatifard, A. (2010). Linking H3K79 trimethylation to Wnt 
signaling through a novel Dot1-containing complex (DotCom). Genes Dev 24, 
574-589. 
Monroe, S., Jo, S., Sanders, D., Basrur, V., Elenitoba-Johnson, K., Slany, R., 
and Hess, J. (2010). MLL-AF9 and MLL-ENL alter the dynamic association of 
transcriptional regulators with genes critical for leukemia. Exp Hematol. 
Morita, S., Kojima, T., and Kitamura, T. (2000). Plat-E: an efficient and stable 
system for transient packaging of retroviruses. Gene Ther 7, 1063-1066. 
Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M., Monroe, S., Sreekumar, A., 
Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J., et al. (2007). A role for the 
MLL fusion partner ENL in transcriptional elongation and chromatin modification. 
Blood 110, 4445-4454. 
Mueller, D., García-Cuéllar, M., Bach, C., Buhl, S., Maethner, E., and Slany, R. 
(2009). Misguided transcriptional elongation causes mixed lineage leukemia. 
PLoS Biol 7, e1000249. 
Muntean, A.G., Giannola, D., Udager, A.M., and Hess, J.L. (2008). The PHD 
fingers of MLL block MLL fusion protein-mediated transformation. Blood 112, 
4690-4693. 
Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., 
Dubois, G., Mazo, A., Croce, C.M., and Canaani, E. (2002). ALL-1 is a histone 
methyltransferase that assembles a supercomplex of proteins involved in 
transcriptional regulation. Mol Cell 10, 1119-1128. 
Ng, H., Feng, Q., Wang, H., Erdjument-Bromage, H., Tempst, P., Zhang, Y., and 
Struhl, K. (2002a). Lysine methylation within the globular domain of histone H3 
 107 
by Dot1 is important for telomeric silencing and Sir protein association. Genes 
Dev 16, 1518-1527. 
Ng, H., Xu, R., Zhang, Y., and Struhl, K. (2002b). Ubiquitination of histone H2B 
by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 
79. J Biol Chem 277, 34655-34657. 
Ng, H.H., Dole, S., and Struhl, K. (2003). The Rtf1 component of the Paf1 
transcriptional elongation complex is required for ubiquitination of histone H2B. J 
Biol Chem 278, 33625-33628. 
Nguyen, A.T., Xiao, B., Neppl, R.L., Kallin, E.M., Li, J., Chen, T., Wang, D.Z., 
Xiao, X., and Zhang, Y. (2011). DOT1L regulates dystrophin expression and is 
critical for cardiac function. Genes Dev 25, 263-274. 
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V., Su, L., Xu, G., and 
Zhang, Y. (2005). hDOT1L links histone methylation to leukemogenesis. Cell 121, 
167-178. 
Okada, Y., Jiang, Q., Lemieux, M., Jeannotte, L., Su, L., and Zhang, Y. (2006). 
Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by 
hDOT1L. Nat Cell Biol 8, 1017-1024. 
Pronk, C., Rossi, D., Månsson, R., Attema, J., Norddahl, G., Chan, C., 
Sigvardsson, M., Weissman, I., and Bryder, D. (2007). Elucidation of the 
phenotypic, functional, and molecular topography of a myeloerythroid progenitor 
cell hierarchy. Cell Stem Cell 1, 428-442. 
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., and 
Preudhomme, C. (2008). Cooperating gene mutations in acute myeloid leukemia: 
a review of the literature. Leukemia 22, 915-931. 
Rozenblatt-Rosen, O., Hughes, C.M., Nannepaga, S.J., Shanmugam, K.S., 
Copeland, T.D., Guszczynski, T., Resau, J.H., and Meyerson, M. (2005). The 
parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell 
Biol 25, 612-620. 
Rubnitz, J.E., Link, M.P., Shuster, J.J., Carroll, A.J., Hakami, N., Frankel, L.S., 
Pullen, D.J., and Cleary, M.L. (1994). Frequency and prognostic significance of 
HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric 
Oncology Group study. Blood 84, 570-573. 
San-Segundo, P.A., and Roeder, G.S. (2000). Role for the silencing protein Dot1 
in meiotic checkpoint control. Mol Biol Cell 11, 3601-3615. 
Sharma, S.V., and Settleman, J. (2010). Exploiting the balance between life and 
death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol 80, 
666-673. 
Shen, F.W., Saga, Y., Litman, G., Freeman, G., Tung, J.S., Cantor, H., and 
Boyse, E.A. (1985). Cloning of Ly-5 cDNA. Proc Natl Acad Sci U S A 82, 7360-
7363. 
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., and Casero, 
R.A. (2004). Histone demethylation mediated by the nuclear amine oxidase 
homolog LSD1. Cell 119, 941-953. 
Shilatifard, A. (2008). Molecular implementation and physiological roles for 
histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20, 341-348. 
 108 
Silverman, L.B. (2007). Acute Lymphoblastic Leukemia in Infancy. Pediatr Blood 
Cancer 49, 1070–1073. 
Singer, M., Kahana, A., Wolf, A., Meisinger, L., Peterson, S., Goggin, C., 
Mahowald, M., and Gottschling, D. (1998). Identification of high-copy disruptors 
of telomeric silencing in Saccharomyces cerevisiae. Genetics 150, 613-632. 
Slany, R.K. (2009). The molecular biology of mixed lineage leukemia. 
Haematologica 94, 984-993. 
So, C.W., Lin, M., Ayton, P.M., Chen, E.H., and Cleary, M.L. (2003). Dimerization 
contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer 
Cell 4, 99-110. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter 
strain. Nat Genet 21, 70-71. 
Steger, D., Lefterova, M., Ying, L., Stonestrom, A., Schupp, M., Zhuo, D., Vakoc, 
A., Kim, J., Chen, J., Lazar, M., et al. (2008). DOT1L/KMT4 recruitment and 
H3K79 methylation are ubiquitously coupled with gene transcription in 
mammalian cells. Mol Cell Biol 28, 2825-2839. 
Taki, T., Ida, K., Bessho, F., Hanada, R., Kikuchi, A., Yamamoto, K., Sako, M., 
Tsuchida, M., Seto, M., Ueda, R., et al. (1996). Frequency and clinical 
significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 
10, 1303-1307. 
Terranova, R., Agherbi, H., Boned, A., Meresse, S., and Djabali, M. (2006). 
Histone and DNA methylation defects at Hox genes in mice expressing a SET 
domain-truncated form of Mll. Proc Natl Acad Sci U S A 103, 6629-6634. 
Thiel, A.T., Blessington, P., Zou, T., Feather, D., Wu, X., Yan, J., Zhang, H., Liu, 
Z., Ernst, P., Koretzky, G.A., et al. (2010). MLL-AF9-induced leukemogenesis 
requires coexpression of the wild-type Mll allele. Cancer Cell 17, 148-159. 
Vakoc, C., Sachdeva, M., Wang, H., and Blobel, G. (2006). Profile of histone 
lysine methylation across transcribed mammalian chromatin. Mol Cell Biol 26, 
9185-9195. 
van Leeuwen, F., Gafken, P., and Gottschling, D. (2002). Dot1p modulates 
silencing in yeast by methylation of the nucleosome core. Cell 109, 745-756. 
Wood, A., Schneider, J., Dover, J., Johnston, M., and Shilatifard, A. (2003). The 
Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 
complex, which signals for histone methylation by COMPASS and Dot1p. J Biol 
Chem 278, 34739-34742. 
Xiao, Y. (2011). Enhancer of zeste homolog 2: A potential target for tumor 
therapy. Int J Biochem Cell Biol 43, 474-477. 
Yokoyama, A., and Cleary, M.L. (2008). Menin critically links MLL proteins with 
LEDGF on cancer-associated target genes. Cancer Cell 14, 36-46. 
Yokoyama, A., Somervaille, T.C., Smith, K.S., Rozenblatt-Rosen, O., Meyerson, 
M., and Cleary, M.L. (2005). The menin tumor suppressor protein is an essential 
oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218. 
Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kitabayashi, I., 
Herr, W., and Cleary, M.L. (2004). Leukemia proto-oncoprotein MLL forms a 
SET1-like histone methyltransferase complex with menin to regulate Hox gene 
expression. Mol Cell Biol 24, 5639-5649. 
 109 
Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., and Korsmeyer, S.J. (1995). 
Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 
505-508. 
Zangrando, A., Dell'orto, M.C., Te Kronnie, G., and Basso, G. (2009). MLL 
rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: 
MLL specific and lineage specific signatures. BMC Med Genomics 2, 36. 
Zeisig, B., Milne, T., García-Cuéllar, M., Schreiner, S., Martin, M., Fuchs, U., 
Borkhardt, A., Chanda, S., Walker, J., Soden, R., et al. (2004). Hoxa9 and Meis1 
are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 24, 
617-628. 
Zhang, W., Xia, X., Reisenauer, M.R., Hemenway, C.S., and Kone, B.C. (2006). 
Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and 
repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem 281, 
18059-18068. 
Zhu, B., Mandal, S.S., Pham, A.D., Zheng, Y., Erdjument-Bromage, H., Batra, 
S.K., Tempst, P., and Reinberg, D. (2005). The human PAF complex coordinates 
transcription with events downstream of RNA synthesis. Genes Dev 19, 1668-
1673. 
 
 
 
 
